Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy Authors: Kaiwen Xiao, Bailing Zhou, Dechao Feng, Shangsong Yang, Sibei Lei, Dilinaer Wusiman, Zhixuan Jiang, Fei Li, Mohan Liu Published: 2026 ABSTRACT AbstractBladder cancer (BCa) management is challenged by high recurrence rates, therapeutic resistance, and the lack of integrated strategies for early diagnosis and effective treatment. Although nanotechnology has been widely explored in oncology, existing reviews largely discuss diagnostic and therapeutic applications separately, with limited attention to how nanomaterial design governs biological performance in the bladder-specific microenvironment. Here, we present a materials-oriented and problem-driven review that systematically connects nanomaterial design with functional outcomes across the diagnostic–therapeutic continuum in BCa. We highlight how tunable physicochemical properties, such as size, surface chemistry, and interfacial behavior enable enhanced urinary biomarker detection, high-resolution imaging, and efficient intravesical drug delivery under dynamic physiological conditions. Particular emphasis is placed on integrated nanotheranostic platforms that combine diagnosis, imaging, and therapy within unified systems, enabling real-time feedback and synergistic treatment. We further discuss key advances in nanocarrier-based chemotherapy, phototherapy, immunomodulation, and gene delivery, with a focus on overcoming bladder-specific barriers including urothelial impermeability, rapid urine-induced clearance, and tumor heterogeneity. In contrast to prior descriptive reviews, this work also addresses translational challenges such as biosafety, reproducibility, and scalable manufacturing, and outlines emerging directions including AI-assisted nanomaterial design and nano-enabled liquid biopsy. Overall, this review provides a conceptual framework linking nanomaterial engineering with clinical needs in BCa, aiming to guide the rational development of next-generation precision nanomedicine.Graphical Abstract Rationally designed nanomaterials enable integrated diagnostic and therapeutic strategies for bladder cancer. For diagnosis, nano-enabled platforms support ultrasensitive urinary biomarker detection, liquid biopsy, and high-resolution multimodal imaging through signal amplification and enhanced specificity. For therapy, nanocarriers with tunable physicochemical properties improve intravesical retention, tumor penetration, and targeted drug delivery, overcoming key barriers including urothelial impermeability, urine dilution, and rapid clearance. Importantly, the integration of diagnostic and therapeutic functions within unified nanotheranostic platforms enables image-guided, personalized, and synergistic treatment Keywords: Bladder cancer, Nanotheranostics, Intravesical drug delivery, Tumor microenvironment, Nanomedicine Introduction Bladder cancer (BCa) remains a major global health burden and is characterized by high recurrence rates, significant treatment-related morbidity, and limited therapeutic efficacy in advanced disease [1]. Despite advances in cystoscopy and intravesical therapy, current diagnostic and therapeutic strategies remain constrained by several intrinsic limitations, including insufficient sensitivity for early detection, poor spatial resolution, invasive procedures, and the inability to achieve sustained and localized drug delivery [2, 3]. In addition, BCa is often considered an immunologically “cold” tumor, with an immunosuppressive microenvironment that contributes to suboptimal responses to immunotherapy [4]. From a physiological perspective, the bladder presents unique challenges that fundamentally limit treatment efficacy. The urothelial barrier restricts molecular penetration, while continuous urine production and voiding lead to rapid dilution and clearance of therapeutic agents. Tumor heterogeneity and a dynamic microenvironment further complicate both diagnosis and treatment. Collectively, these factors highlight the need for delivery systems capable of overcoming physical barriers while enabling precise, sustained, and controllable intervention. Nanomaterials offer a promising solution to these challenges due to their tunable physicochemical properties and programmable interfacial interactions [5]. By precisely controlling parameters such as size, morphology, and surface chemistry, nanoplatforms can modulate biological behaviors including tissue penetration, cellular uptake, and drug release kinetics (Fig. 1). Beyond single-function delivery, nanomaterials enable the integration of multiple functionalities, such as imaging, targeting, and therapy, within a unified system, providing a foundation for theranostic strategies [6–8]. However, most existing reviews in this field primarily summarize nanotechnology applications in isolated domains (diagnosis or therapy), or focus on specific material categories, without fully addressing how nanomaterial design translates into functional performance in the context of BCa. Moreover, the unique physiological characteristics of the bladder and their implications for nanomedicine design have not been systematically integrated into current frameworks. Representative nanomaterial platforms and their multifunctional roles in precision nanomedicine for bladder cancer. Inorganic nanomaterials, including metal nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), upconversion nanoparticles (UCNPs), quantum dots (QDs), and mesoporous silica nanoparticles (MSNs), offer versatile platforms for integrated diagnosis and therapy owing to their high surface area, tunable optical or magnetic properties, and facile surface functionalization, enabling applications such as targeted drug delivery, photothermal/photodynamic therapy, magnetic hyperthermia, and multimodal imaging. Organic nanomaterials, such as polymeric nanoparticles or micelles, liposomes, dendrimers, biomimetic nanoparticles and protein/peptide-based nanocarriers, provide excellent biocompatibility and structural flexibility for the controlled delivery of chemotherapeutics, nucleic acids, immunomodulators, and imaging agents. Together, these nanomaterial platforms enable targeted delivery, intelligent imaging, and synergistic therapeutic strategies for bladder cancer management Nanomaterials possess a unique combination of tunable physicochemical parameters and programmable interfacial behaviors that make them intrinsically suited for addressing the material-level challenges associated with BCa. Beyond single-function delivery, nanomaterials provide a modular platform for the rational assembly of multimodal functionalities, including real-time imaging, stimulus-responsive activation, and the coordinated deployment of multiple therapeutic mechanisms. By integrating complementary diagnostic and therapeutic components within a unified material framework, multimodal nanoplatforms enable cross-correlated signal transduction, a more comprehensive mapping of tumor structure and microenvironmental dynamics, and synergistic therapeutic interactions among chemical, photonic, and immunological mechanisms. Importantly, the intrinsic coupling of imaging and therapeutic functions within these material systems allows real-time feedback between structural activation and biological response, providing a materials-based foundation for adaptive and optimized BCa intervention. In this review, we adopt a materials-oriented and problem-driven perspective to bridge this gap. Specifically, we focus on elucidating the structure–function relationships of nanomaterials in the bladder microenvironment; highlighting integrated nanotheranostic platforms that couple diagnosis, imaging, and therapy; and linking nanoplatform design to key clinical challenges, including urothelial barriers, urine-induced clearance, tumor heterogeneity, and immunosuppressive microenvironment [9, 10]. Furthermore, we extend beyond conventional descriptive summaries by incorporating translational considerations such as biosafety, reproducibility, and clinical scalability, and by discussing emerging directions including AI-assisted nanomaterial design and nano-enabled liquid biopsy [11]. Through this integrated framework, we aim to provide a clearer roadmap for the rational development and clinical translation of nanotechnology-based precision strategies in BCa. Major hallmarks in bladder cancer therapy Therapeutic efficacy in urinary BCa is fundamentally constrained by the unique biological and physicochemical barriers of the bladder. While these barriers protect underlying tissues, they also severely limit material transport, retention, and bioavailability. Addressing these constraints requires rationally engineered nanomaterials with controlled size, surface properties, and interfacial interactions. Precision-designed nanoparticles offer a materials-based strategy to modulate barrier penetration and local retention, thereby improving delivery efficiency and functional performance (Fig. 2). Biological barriers in bladder cancer and nano-enabled strategies. A. Urothelial barrier. The umbrella cell layer, together with the glycosaminoglycan (GAG) coating and tight junctions, forms a high-resistance interface that restricts drug permeation and promotes rapid clearance via subepithelial capillary flow. B. Dynamic washout. Continuous urine turnover and voiding rapidly remove intravesically administered agents, shortening urothelial contact time and limiting local retention. C. Immunosuppressive tumor microenvironment (TME). Hypoxia, acidic pH, dense extracellular matrix, and suppressive immune populations hinder material penetration and therapeutic efficacy, motivating nanomaterial designs that enhance transport, retention, and immune modulation. Created with BioRender.com Bladder urothelial barrier The bladder epithelium consists of three distinct cell layers, which from the inside out are the superficial layer, intermediate layer, and basal layer [12, 13]. The inner surface of the urinary bladder is lined with a highly specialized layer of stratified epithelial cells known as the urothelium [14]. Although the bladder epithelium is multilayered, its primary barrier function is performed by the outermost umbrella cell layer [15]. This layer includes the apical membrane structure of umbrella cells, the glycosaminoglycan (GAG) layer on its surface, and the tight junctions (TJs) between umbrella cells. The TJs, together with the apical membrane of umbrella cells, form a high-resistance barrier against ions, molecules, and pathogens in the urine [16]. Moreover, drugs that do manage to diffuse into the deeper layers are rapidly cleared by capillary flow, leading to a decreased drug concentration gradient [17, 18]. Dynamic environment The continuous urine flow and frequent emptying of bladder can rapidly dilute and remove drug formulations, reducing pharmaceutical absorption across the urothelium [19]. The constant cycling of urine through the bladder during normal voiding leads to the continual washout of therapeutic agents, limiting their contact time with the urothelium [18, 20]. Furthermore, agents that do penetrate the urothelium are not retained in the muscularis propria and are quickly cleared by capillaries, reducing their efficacy on the bladder wall and causing systemic absorption and associated adverse effects [21]. Additionally, the continuous flow of urine inevitably dilutes any administered agent, even prior to complete elimination during urination. Basic strategies, such as increasing the drug dosage, reducing urine volume by restricting fluids, and alkalinizing the urine to stabilize the drug, have demonstrated improved drug delivery and a reduced recurrence rate in BCa [22, 23]. Low response rate to immunotherapy A subdued response to immunotherapy presents a significant clinical challenge, with only 20–30% of patients showing a positive response. This limited response is often due to the immunosuppressive TME and the highly heterogeneity of bladder tumors. The TME is known to facilitate cellular mechanisms that contribute to drug resistance, such as the expression of drug efflux pumps and the activation of survival pathways. Various factors within the microenvironment, such as hypoxia, acidic pH, and dense extracellular matrix, hinder the penetration and efficacy of therapeutic agents. Additionally, the immune cells within the TME can also contribute to drug resistance and immunosuppressive cells and signals can protect cancer cells from the effects of immunotherapy and other combination treatments. Advanced nanomaterial platforms for bladder cancer theranostics The performance of multimodal nanotheranostic systems is primarily governed by the intrinsic physicochemical characteristics of their core nanoplatforms (Fig. 1). Representative nanomaterials offer favorable biocompatibility, biodegradability, and adaptable architectures for encapsulating both hydrophilic and hydrophobic cargos, thereby enabling controlled release and combinatorial functionality (Table 1). Table 1Classification and comparative analysis of nanomaterials for bladder cancer applicationsNanomaterial platformRepresentative systemsKey advantages in BCaMajor limitationsTherapeutic/Diagnostic potentialTranslational challenges Inorganic nanoparticles Gold nanorods, iron oxide NPs, upconversion nanoparticles, MOFsHigh structural stability; tunable optical/magnetic properties; excellent imaging contrast (MRI/PAI/SERS); photothermal/photodynamic capabilitiesPotential long-term toxicity; poor biodegradability; accumulation in organsImaging-guided therapy; PTT/PDT; biosensing; nanozyme-based catalysisBiosafety concerns; unclear metabolism; regulatory barriers for inorganic materials Polymeric nanoparticles PLGA-PEG NPs, chitosan-based systems, hyperbranched polyglycerolsGood biocompatibility; tunable degradation; high drug loading; flexible functionalization; mucoadhesion for intravesical deliveryBurst release; limited structural uniformity; possible instability in urine environmentIntravesical chemotherapy; sustained release; gene delivery; barrier modulationBatch variability; scale-up reproducibility; formulation complexity Lipid-based nanoparticles Liposomes, mRNA-LNPs, hybrid lipid nanocarriersExcellent biocompatibility; efficient nucleic acid delivery; clinically validated platforms; good membrane fusion abilityLimited stability; leakage; relatively low mechanical robustness; rapid clearance in bladdermRNA/siRNA delivery; immunotherapy; combination therapyStorage stability; manufacturing consistency; cost and cold-chain requirements Hybrid nanostructures Polymer–metal hybrids, lipid-coated inorganic NPsCombine advantages of multiple systems; multifunctionality (imaging + therapy); improved stability and targetingIncreased structural complexity; difficult characterization; potential safety concernsMultimodal theranostics; synergistic therapy (PTT + chemo + immunotherapy)Complex manufacturing; regulatory classification challenges; reproducibility issues Biomimetic nanoplatforms RBC membrane-coated NPs, cancer cell membrane-coated NPs, exosomesImmune evasion; homologous targeting; high biocompatibility; improved retention and penetrationSource variability; limited scalability; stability issuesTargeted delivery; immunomodulation; precision therapy; liquid biopsy applicationsStandardization of biological sources; large-scale production; regulatory uncertainty Classification and comparative analysis of nanomaterials for bladder cancer applications Inorganic nanomaterials Metal nanoparticles Metal-based nanomaterials possess unique physicochemical properties including size effects, surface effects, and localized surface plasmon resonance (LSPR) [24–31]. The high surface-to-volume ratio of metal nanoparticles enhances catalytic activity, drug loading capacity, and interactions with biological components. The quantum size effect leads to discretized electronic energy levels, resulting in size-tunable optical, electrical, and magnetic characteristics. A notable manifestation of this effect is the size‑tunable LSPR, which arises from collective oscillation of conduction electrons and can be precisely adjusted across the visible to near‑infrared spectral range by controlling nanoparticle size and morphology [31]. Morphological engineering (rods, stars, cubes, cages) further enables anisotropic nanostructures that generate significantly enhanced local electric fields [32, 33]. Hybrid systems, such as metal complex–metal nanoparticle assemblies, allow precise control over interfacial electronic interactions, often producing synergistic effects for catalytic, sensing, and biomedical applications. The continuous refinement of synthetic methodologies enables precise architectural control over size, shape, and composition, positioning metal nanoparticles as a highly versatile platform for developing advanced theranostic strategies in BCa. Superparamagnetic iron oxide nanoparticles Superparamagnetic iron oxide nanoparticles (SPIONs) represent a cornerstone theranostic platform, uniquely integrating sensitive diagnosis and targeted therapy for bladder cancer [34]. Their superparamagnetic core enables powerful T2‑weighted MRI, functioning as a negative contrast agent for high‑resolution tumor visualization [35]. Crucially, SPIONs efficiently convert externally applied alternating magnetic field (AMF) energy into localized heat via magnetic hyperthermia therapy, primarily through Néel and Brownian relaxation losses [36]. This heat generation can induce tumor cell death while sparing surrounding healthy tissue. By applying external static magnetic field gradients, SPION accumulation can be precisely directed to bladder tumor sites. This magnetic targeting strategy counteracts physiological barriers such as urine flow‑induced washout, thereby improving localized therapeutic delivery compared with passive diffusion‑based systems [37]. The synergy of MRI guidance, spatially confined thermal therapy, and magnetic targeting underpins the significant potential of SPIONs for precision BCa management, addressing key challenges including insufficient tumor accumulation and limited treatment specificity. Quantum dots Quantum dots (QDs) are semiconductor nanocrystals that exhibit distinctive optoelectronic properties due to quantum confinement effects, which become pronounced when their dimensions fall below the Bohr exciton radius [38]. This confinement of electrons and holes in three dimensions results in discrete energy levels and a size‑tunable bandgap, allowing precise control of photoluminescence emission across the visible to near‑infrared spectrum simply by varying the core size [39, 40]. Complementing this tunability are high molar extinction coefficients (conferring brightness), narrow and symmetric emission bands, large Stokes shifts, and exceptional resistance to photobleaching—making QDs vastly superior to conventional organic fluorophores for prolonged imaging [41]. Surface engineering is critical for QD performance. The high surface‑to‑volume ratio means many surface atoms possess unsaturated bonds, creating trap states that facilitate non‑radiative recombination and reduce photoluminescence quantum yield [42]. Therefore, sophisticated passivation strategies are essential. A common approach involves growing an inorganic shell with a wider bandgap (e.g., CdS or ZnS) around the core to create a core/shell structure that confines charge carriers and eliminates surface defects [43]. Furthermore, native hydrophobic ligands must be exchanged for hydrophilic molecules (e.g., glutathione) to enable aqueous solubility and provide functional groups for bioconjugation with antibodies, peptides, or DNA [44, 45]. The continuous exploration of novel compositions—including carbon‑based, perovskite, and MXene‑derived QDs—further expands the toolkit for tailored theranostic applications. Upconversion nanoparticles Upconversion nanoparticles (UCNPs) convert lower-energy near-infrared (NIR) photons into higher-energy visible or ultraviolet light through a nonlinear anti-Stokes process [46, 47]. This upconversion luminescence is primarily achieved in inorganic host matrices (e.g., NaYF₄) doped with trivalent lanthanide ions such as ytterbium (Yb³⁺) as sensitizers and erbium (Er³⁺) or thulium (Tm³⁺) as activators [48, 49]. The long-lived intermediate energy states of these ions allow sequential absorption of multiple NIR photons. The host matrix with low phonon energy minimizes non-radiative relaxation, significantly enhancing upconversion efficiency [50]. Material composition and architectural design are central to tuning UCNP photophysical properties. In addition to core-only structures, sophisticated core–shell architectures suppress surface-related quenching and isolate the luminescent core from the environment [51]. Doping with other lanthanides (e.g., Ce³⁺) can further manipulate emission profiles and intensities [52]. For biological applications, surface functionalization is essential. As-synthesized UCNPs are typically hydrophobic and require ligand engineering (e.g., ligand oxidation, silica coating, or layer‑by‑layer assembly) to render them water‑dispersible and biocompatible [53, 54]. Subsequent bioconjugation with antibodies, peptides, or other biomolecules enables active targeting. The unique photophysical properties of UCNPs—including high photostability, deep tissue penetration of NIR excitation, minimal background autofluorescence, and the absence of toxic blinking—make them exceptionally attractive for biomedical applications [55, 56]. Their large surface area supports multifunctionalization, and they can serve as efficient energy donors in FRET‑based biosensing platforms, where NIR excitation avoids direct excitation of biological samples and reduces background noise [57]. These attributes position UCNPs as valuable platforms for low‑background imaging and spatiotemporally controlled therapy. T. Mesoporous silica nanoparticles Mesoporous silica nanoparticles (MSNs) are characterized by highly ordered porous structures, tunable pore diameters, and exceptional surface properties, making them ideal candidates for drug delivery, imaging, and theranostic applications in oncology [58]. Their large specific surface area and substantial pore volume enable high loading capacities for diverse therapeutic agents, including chemotherapeutic drugs, nucleic acids, and proteins [59]. Synthetic versatility allows precise control over particle size (50–300 nm), morphology (spherical, rod-like, or hollow), and surface chemistry, which are critical for modulating biological interactions and optimizing performance in complex physiological environments. The silica‑based matrix offers inherent biocompatibility and stability, while surface functionalization strategies (e.g., grafting with organosilanes) facilitate enhanced mucoadhesion, targeted delivery, and stimuli‑responsive behavior [60]. A defining feature of MSNs is their capacity for engineered drug release kinetics, achieved through pore‑gating mechanisms or surface modifications that respond to endogenous stimuli (pH, redox potential, enzymes) or exogenous stimuli (light, magnetic fields) [61]. The silica surface, rich in silanol groups, serves as a platform for conjugating targeting ligands and functional polymers (e.g., polyethyleneimine, polyethylene glycol) to improve colloidal stability, prolong circulation half‑life, and enhance tumor‑specific accumulation [62]. Moreover, the porous framework can accommodate contrast agents, enabling dual‑mode imaging capabilities such as fluorescence bioimaging and MRI. This synergy between diagnostic and therapeutic functions positions MSNs as pivotal tools in theranostics, where real‑time monitoring and controlled intervention are unified within a single nanoplatform. Carbon-based nanomaterials Carbon-based nanomaterials, including graphene oxide (GO), reduced GO (rGO), carbon dots (CDs), and carbon nanotubes (CNTs), constitute a versatile class of theranostic agents for precision BCa management [63]. Their prominent application lies in exceptional photothermal properties, which are highly effective for photothermal therapy (PTT). These materials exhibit strong near-infrared (NIR) absorption, enabling efficient conversion of light into localized hyperthermia to selectively ablate tumor cells [64, 65]. Complementing their photothermal capabilities, carbon-based nanomaterials offer multi‑modal imaging functions. CDs demonstrate tunable, stable fluorescence ideal for real‑time optical imaging, while GO, rGO, and CNTs serve as excellent contrast agents for photoacoustic imaging (PAI) due to their high photothermal conversion efficiency, allowing deep‑tissue tumor visualization with high spatial resolution. The large specific surface area of graphene‑based materials and CNTs facilitates substantial drug loading of chemotherapeutic agents, genes, or immunomodulators, enabling targeted combination therapy. Functionalization with polymers (e.g., PEG) or targeting ligands further enhances stability, biocompatibility, and tumor‑specific accumulation. Despite challenges in long‑term toxicity and clinical translation, the unique integration of photothermal ablation, imaging guidance, and drug delivery within a single carbon‑based platform exemplifies a powerful approach for achieving targeted, image‑guided synergistic BCa therapy. Organic nanomaterials Liposomes Liposomes, self-assembled phospholipid bilayer vesicles, constitute a clinically validated and highly versatile nanoplatform central to implementing precision strategies for BCa administration [66]. Their foremost advantage lies in exceptional biocompatibility and biodegradability derived from natural lipid composition, minimizing systemic toxicity and enhancing clinical translatability [67]. Liposomes exhibit remarkably high loading capacity for both hydrophilic and hydrophobic agents, enabling efficient co‑delivery of diverse therapeutic cargos and diagnostic agents [68]. Lipid nanoparticles (LNPs) have been clinically validated to effectively deliver both siRNA and larger mRNA for cancer therapy. Early work demonstrated that cationic liposomes (e.g., DOTMA) significantly enhance nucleic acid loading and delivery [67], and lipofectin (DOTMA: DOPE 1:1) enabled efficient mRNA transfection [69]. Today, LNPs typically consist of a lipid mixture containing ionizable lipids, phospholipids, cholesterol, and PEGylated lipids [70, 71]. Ionizable lipids are the primary component, initiating electrostatic binding with endosomal membranes and facilitating cytosolic release [72]. They contain an ionizable head group (tertiary amines that protonate at acidic pH but remain neutral at physiological pH), a linker area (ether, ester, amide, disulfide, etc., influencing stability and biodegradability), and hydrocarbon tails (hydrophobic interactions stabilizing LNP structure and preventing drug leakage) [73, 74]. Adjusting tail length and saturation can enhance LNP stability—longer or more saturated tails generally increase rigidity and reduce leakage risk [75, 76]. Phospholipids (e.g., DOPE, DSPC) support bilayer formation, cholesterol modulates membrane fluidity and stability, and PEGylated lipids prolong circulation half‑life by reducing protein adsorption and immunogenicity. These structural and compositional features make liposomes and LNPs highly adaptable platforms for BCa therapy, supporting chemotherapy, immunotherapy, and nucleic acid delivery. [77]. Polymeric nanoparticles Polymeric nanoparticles (PNPs), encompassing both nanospheres and nanocapsules, are characterized by a large specific surface area resulting from their minute volume, which dramatically increases the percentage of surface‑located atoms or molecules and fundamentally enhances interfacial interactions with biological systems [78]. The material essence of PNPs lies in versatile macromolecular architectures that can be precisely engineered through controlled polymerization techniques and self‑assembly processes, enabling the formation of nanoparticles with tailored physicochemical properties. The synthesis of PNPs employs polymerization‑based methods, representing the predominant strategy for producing well‑defined nanostructures [79]. Poly(alkylcyanoacrylate) (PACA) is among the most extensively characterized polymers for nanoparticle fabrication, with a comprehensive understanding of polymerization kinetics and conditions necessary to achieve precise characteristics [80]. These methods have evolved to include environmentally friendly approaches utilizing ultrasonic and microwave irradiation to control particle formation [81]. A particularly advanced manifestation is the development of single‑chain polymer nanoparticles (SCNPs), which mimic protein‑like folded structures through amphiphilic self‑assembly of ultra‑high‑molecular‑weight graft copolymers [82]. SCNPs, typically 10–15 nm in diameter, exhibit unique physical properties including extraordinary amphiphilic character, extremely low viscosity, and remarkable structural stability in biological environments [83]. The synthesis of such sophisticated PNPs often incorporates “click chemistry” strategies and functional polymers (e.g., glycidyl azide polymers, polyethylene glycol) to achieve precise architectural control [84]. Dendrimers Dendrimers possess a synthetically precise, highly branched nanostructure that affords unique capabilities for BCa management [85]. These macromolecules are constructed through iterative synthesis methods, resulting in a well-defined core, layered branching units (generations), and a high-density array of surface functional groups [86]. The stepwise synthetic control achieved via divergent or convergent strategies enables precise tuning of dendrimer size (typically 1–15 nm for generations G0–G10), surface charge, and hydrophobicity‑hydrophilicity balance [87, 88]. With their globular morphology for hosting hydrophobic drugs and abundant surface groups for covalent modification, dendrimers constitute a versatile nanoplatform. This modular design ensures not only high drug‑loading efficiency but also the ability to precisely tailor biodistribution profiles. Dendritic branching and molecular crowding dictate the internal structure of dendrimers, creating distinct microenvironments that vary between the core and the surface. Through techniques like molecular topology modeling and Omega polynomial analysis, this arrangement reveals an emergent hierarchical organization, wherein monomers self‑assemble into stable supramolecular nanostructures [89]. Owing to their well‑defined, three‑dimensional nanostructure, dendrimers exhibit significant surface effects that enhance multivalent binding through densely packed terminal groups. Coupled with a low polydispersity index (ensuring reproducible pharmacokinetics) and nanoscale dimensions that promote cellular internalization and nuclear access, these properties collectively underpin their biological efficacy, as evidenced by elevated cytoplasmic diffusion coefficients in carcinoma cells [90]. Peptide nanoplatform Peptide-based nanoparticles derive their functionality from materials inherent to biological systems, integrating structural control, inherent bioactivity, and targeting capabilities with high biocompatibility [91]. They are primarily constructed from amphiphilic peptides that spontaneously organize into core‑shell architectures in aqueous environments, where hydrophobic domains aggregate to form the nanoparticle core (enabling efficient encapsulation of lipophilic therapeutic agents), while hydrophilic segments stabilize the nanoparticle surface and facilitate aqueous dispersion [92]. The structural integrity and morphological diversity of peptide nanoparticles—ranging from spherical nanomicelles to fibrous hydrogels—are governed by non‑covalent interactions including hydrogen bonding, π‑π stacking, electrostatic forces, and hydrophobic effects, which can be precisely modulated through sequence design to control particle size, shape, and mechanical properties. A distinctive advantage of peptide‑based platforms is their modular capacity for multi‑functionalization. Specific peptide motifs can be integrated into the nanoparticle design to confer active targeting capabilities via ligands that bind overexpressed receptors on bladder cancer cells, enhance tissue penetration through cell‑penetrating peptides (e.g., oligoarginine R₉), and introduce environmental responsiveness to physiological stimuli such as pH, enzymes, or redox gradients. Many proteins (e.g., albumin, ferritin) and engineered peptides possess innate tumor‑homing properties or can be precisely designed to recognize specific biomarkers overexpressed on BCa cells (e.g., EGFR, CD44), facilitating highly specific active targeting without extensive surface modification. Furthermore, these nanomaterials exhibit superior biocompatibility and low immunogenicity, as they are primarily composed of natural amino acids, thereby minimizing potential systemic toxicity and enhancing clinical translation potential. Their inherent biodegradability into non‑toxic metabolic byproducts ensures excellent safety profiles and avoids long‑term accumulation concerns. The versatile structure of these building blocks allows for self‑assembly into well‑defined nanoparticles capable of encapsulating or conjugating diverse therapeutic cargos (e.g., chemotherapeutics, toxins, siRNA) and diagnostic agents (e.g., near‑infrared dyes, MRI contrast agents). This multifunctionality supports the development of potent theranostic systems for targeted delivery, enhanced imaging contrast, and therapeutic synergy. Their surfaces can also be further engineered to incorporate stimuli‑responsive elements for controlled drug release within the tumor microenvironment. The combination of natural targeting, exceptional safety, and modular design positions peptide nanoplatforms as a transformative and clinically viable strategy for implementing precision BCa management. Biomimetic nanostrategies Biomimetic nanotechnology has emerged as an effective strategy to overcome fundamental biological barriers in bladder cancer (BCa), particularly immune clearance, limited targeting specificity, and inefficient urothelial penetration. By integrating synthetic nanomaterials with biologically derived membranes or vesicles, these systems leverage endogenous biological functions to improve delivery efficiency and therapeutic precision [93]. Initial efforts primarily focused on red blood cell (RBC) membrane coating to prolong circulation and evade immune recognition. While these early systems improved pharmacokinetics, their therapeutic impact remained limited due to a lack of active targeting or functional integration. More recent designs have therefore moved beyond passive “stealth” behavior toward multifunctional delivery platforms. For example, RBC membrane–camouflaged nanoparticles have been engineered to co-deliver chemotherapeutic agents or combine chemotherapy with photodynamic therapy, enabling coordinated therapeutic effects while maintaining immune evasion [94]. Building on this concept, hybrid biomimetic systems have been developed to overcome the limited functional flexibility of membrane-only platforms, which often have low drug-loading capacity. RBC membrane vesicle–fused lipid nanoparticles integrate the long-circulation advantage of RBC membranes with the high cargo-loading capacity of lipid nanocarriers, enabling efficient delivery of nucleic acids and immunomodulators [95]. This hybrid design not only enhances systemic stability but also improves tumor accumulation and functional delivery efficiency, making it particularly suitable for advanced or metastatic BCa settings where multiple barriers exist. While RBC-based systems primarily address immune clearance, they do not inherently provide tumor specificity. To overcome this limitation, cancer cell membrane–coated nanoparticles have been developed to exploit homologous targeting mechanisms. By preserving tumor-associated antigens and adhesion molecules, these platforms enable preferential recognition of source tumor cells, thereby enhancing targeting precision and cellular uptake [96]. In the context of BCa, such homotypic interactions are particularly valuable for improving intravesical retention and selective tumor accumulation, where conventional targeting strategies often fail [97]. Beyond membrane coating strategies, extracellular vesicle (EV)-based nanoplatforms represent a further evolution toward fully endogenous delivery systems. Owing to their intrinsic role in intercellular communication, EVs possess natural capabilities for transporting proteins, lipids, and nucleic acids, enabling efficient and biologically compatible cargo delivery [98]. Importantly, EVs also function as diagnostic carriers in liquid biopsy, reflecting the molecular signatures of parental tumor cells and supporting non-invasive detection of BCa biomarkers [99]. This dual functionality positions EVs as a central component in integrated theranostic strategies, solving both delivery and diagnostic challenges simultaneously. Diagnostic applications Early detection of BCa is limited by tumor heterogeneity and the intrinsic sensitivity constraints of conventional assays. Nanomaterial-based biosensing platforms address these limitations through their distinctive physicochemical attributes, including high surface-to-volume ratios, tunable surface chemistry, and efficient signal amplification. The integration of functional nanomaterials with molecular recognition units enables selective and ultrasensitive transduction of BCa-associated biomarkers from urine, blood, and tissue samples. Beyond improved analytical sensitivity, nanomaterial systems support multiplexed detection and dynamic signal readout, highlighting the role of nanomaterial design in advancing robust and information-rich biomarker analysis. Importantly, these systems also support multiplexed analysis and dynamic signal readout, providing more comprehensive diagnostic information. A comparative summary of diagnostic performance metrics across different nanoplatforms is provided in Table 2, facilitating assessment of their clinical diagnostic value. Table 2Summary of nanomaterial-enabled in vitro diagnostic applications for bladder cancerApplication categoryEnabling nanotechnology/PlatformDiagnostic performance (Sensitivity/Specificity/AUC)Key performance metricsClinical diagnostic value (Interpretation)Primary advantage for BCa diagnosis Biomarker detection in urine AuNPs@OMC/Thi@Gr-COOH electrochemical immunosensor [207]NR/NR/NRLOD: 2.96 × 10⁻⁸ ng mL⁻¹ (NMP22)High analytical sensitivity but lacks clinical validation dataStable detection in urine; suitable for repeated testingTetrahedral DNA framework magnetic platform [102]87.3%/91.6%/~0.90Efficient multi-CTC captureClinically promising for CTC-based diagnosis with balanced sensitivity/specificityCaptures epithelial & mesenchymal CTCsM13 bacteriophage-engineered interface with boronate affinity chemistry [103]85.9%/89.4%/~0.88Viable CTC recoveryComparable to TDF systems; suitable for downstream functional analysisPreserves cell integrityGold nanoarray with molecularly imprinted polymers [105]96.2%/98.5%/~0.9897.37% accuracyAmong the highest-performing platforms for early detectionLabel-free exosome profilingMOF-on-MOF asymmetric impinging stream chip [99]~ 85–92%/~80–88%/0.80–0.8430 min enrichmentModerate accuracy but high practicality (rapid processing)High-throughput exosome isolationGold nanoflower (AuNF) electrochemical sensor [107]NR/NR/NRLOD: 0.1 fM (miRNA)Ultra-sensitive but lacks clinical cohort validationmiRNA detection with signal amplificationUrease-powered magnetic nanomotors [108]NR/NR/NRDual-miRNA detection (29–362 fM)Conceptually innovative; clinical relevance yet to be establishedActive propulsion enhances captureSmartphone MEXPAR microgel platform [109]~ 88–94%/~85–90%/~0.904 miRNA multiplex detectionStrong potential for point-of-care testing (POCT)Low sample volume, portableAgAu@Ag triangular nanonet SERS immunosensor [110]~ 92–95%/~90–93%/~0.94fg/mL sensitivityHigh value for non-invasive stratificationDual-protein detectionNanoparticle-protein corona with ProteoTransferNet [111]NR/NR/0.996Multi-omics integrationNear-clinical-level diagnostic performanceAI-enhanced classification Multimodal nanoprobes for cellular imaging & analysis Fluorinated Albumin Nanocages [112]NR/NR/NRNIR-II FI/PAIPrimarily research-stage; strong mechanistic insightTumor–stroma visualizationMRI-Guided Platforms (e.g., T2/DWI) [113]> 90% specificityMIBC vs. NMIBC differentiationClinically established imaging benchmarkDeep-tissue anatomical imagingRiboflavin-Functionalized NPs (RFA@DHA NPs) [114]NR/NR/NR3.1× signal enhancementUseful for mechanistic studies rather than diagnosis aloneROS trackingCopper-based Hybrid Nanozymes (CuSR4M) [115]NR/NR/NRImmune marker trackingValuable for immune response monitoringPD-L1/CCL5 dynamicsX-ray-activated Nanotransducers (cRGD-NaGdF₄:Ce/Tb/Nd@RB) [10]NR/NR/NRImaging-guided PDTTheranostic platform; diagnostic role is supportiveReal-time therapy monitoringNR: not reported Summary of nanomaterial-enabled in vitro diagnostic applications for bladder cancer NR: not reported Detection of BCa biomarkers based on nanomaterials Nanocapture of circulating tumor cells in urine samples The low abundance and high heterogeneity of circulating tumor cells (CTCs) in urine limit the clinical utility of liquid biopsy for BCa diagnosis. Nevertheless, nanotechnology-based platforms offer a promising approach to enhance the detection and capture of urinary CTCs, providing a non-invasive strategy for BCa diagnosis and monitoring [100, 101]. Recent advances have focused on developing highly sensitive and specific nanosensors that leverage the unique properties of nanomaterials for efficient CTC isolation from urine samples. To address the challenges of CTC heterogeneity and low abundance, a tetrahedral DNA framework (TDF)-based magnetic separation platform integrated with a microfluidic device was developed for multivalent CTC capture using aptamers targeting EpCAM, Vimentin, and EGFR. This approach allows for efficient isolation of epithelial and mesenchymal CTCs, facilitating downstream molecular analysis [102]. For clinical diagnostic performance, the tetrahedral DNA framework-based magnetic separation platform achieved a reported sensitivity of 87.3% and specificity of 91.6% in a cohort of 120 BCa patients and 80 healthy controls (data from original study). The NataFace platform demonstrated comparable performance (sensitivity 85.9%, specificity 89.4%) (Fig. 3A) [103]. Overall, these nanoplatforms significantly improve the sensitivity and reliability of CTC detection compared to conventional methods. However, challenges related to standardization, throughput, and clinical validation remain, and their routine application in clinical diagnostics is still limited. Representative nanotechnology-based strategies in bladder cancer diagnostics. A. NataFace captures, detects, and releases CTCs using M13 phage modified with CPBA, Avidin, and DNA switches. It offers efficient capture via multivalency, immediate detection via switch activation, and non-destructive release of live cells using acidic fructose. Reproduced with permission from ref. [103], copyright 2025 American Chemical Society. B. ProteoTransNet enhances bladder cancer (BC) diagnosis by integrating serum and urine proteomic data via transfer learning, based on DIA LC − MS/MS databases built using ProteoFish. Reproduced with permission from ref. [111], copyright 2025 Elsevier. C. Bio-distribution evaluation of free ICG or Cu(OH)2/ICG@M in tumor-bearing mice. Reproduced with permission from ref. [115], copyright 2025 Elsevier. D. Tumour regression by non-invasive single-f-PDT. Reproduced with permission from ref. [10], copyright 2024 Springer Sensitive detection of BCa urinary biomarkers The nanotechnological isolation, enrichment, and subsequent high-sensitivity detection of biomarker cargo within urine-derived exosomes represent a cornerstone of non-invasive liquid biopsy for BCa precision medicine. Traditional isolation methods like ultracentrifugation suffer from lengthy processing times, low yield, and co-precipitation of contaminants [104]. To overcome this, advanced nanomaterial-based capture platforms have been engineered. A gold nanoarray modified with molecularly imprinted polymers allows rapid isolation and label-free analysis of single exosomes via SERS, achieving 97.37% accuracy in early BCa detection using AI-assisted spectral classification [105]. This corresponds to a diagnostic sensitivity of 96.2% and specificity of 98.5% for discriminating BCa from benign conditions. While this platform enables high-sensitivity detection, it still relies on relatively complex spectral analysis and lacks rapid processing capability.A MOF-on-MOF-based asymmetric impinging stream chip enables rapid enrichment of urinary exosomes (10 mL within 30 min) without pre-concentration, facilitating downstream analysis of lncRNAs such as NORAD. NORAD-based models show improved diagnostic performance for BCa (AUC ≈ 0.80–0.84) with higher sensitivity than FISH and cytology, and further gains when combined (up to 98.1%), although clinical translation still requires standardization and large-scale validation. [99]. The extremely low abundance of exosomal microRNAs and proteins in urine poses a significant detection challenge, thereby requiring signal amplification strategies that exceed the limits of conventional methods. Electrochemical nano-sensing interfaces functionalized with nanomaterials exhibit high sensitivity for detecting exosomal microRNAs and proteins, leveraging mechanisms such as voltammetry, impedance spectroscopy, and electrochemiluminescence [106]. For miRNA detection, a catalytic hairpin assembly (CHA)-based electrochemical biosensor on a gold nanoflower (AuNF)-modified electrode has been developed. This platform can detect specific BCa-associated miRNAs miR-21-5p at a minimum detection limit of 0.1 f. and linear range of 0.2 f. ~ 0.2 nM, leveraging the exponential amplification effect of CHA and the superior electrocatalytic activity and large surface area of AuNF [107]. Taken together, these nanotechnology-driven approaches—spanning SERS, electrochemical sensors, and microfluidic enrichment platforms—offer robust, non-invasive tools for BCa biomarker detection with high specificity and sensitivity, paving the way for clinical translation. Nano-sensing platform for tumor markers in free DNA/RNA/protein in urine The development of highly specific and sensitive sensing platforms is crucial for detecting urine-derived biomarkers in BCa, such as cell-free DNA, RNA, and proteins. For instance, urease-powered magnetic nanomotors were developed for the simultaneous detection of BCa biomarkers miRNA-21 and miRNA-182 in urine [108]. Composed of gold nanorods, mesoporous organosilica, Fe₃O₄, and hairpin DNA probes, the nanomotors exhibit urea-enhanced propulsion that improves miRNA capture efficiency. Following magnetic enrichment, the platform enables sensitive dual-miRNA quantification with detection limits of 29 fM and 362 fM, respectively, providing a reliable noninvasive strategy for BCa diagnosis via urine analysis [108]. Moreover, a smartphone-based fluorescent imaging platform combined with multiplexed isothermal exponential amplification (MEXPAR) and microgel-based enrichment enabled simultaneous quantification of four miRNAs (let-7a, miRNA-155, −223, and −143) with a wide linear range (50 fM–30 nM) and minimal sample volume (~5 µL), demonstrating high accuracy in distinguishing BCa patients from healthy controls [109]. For protein biomarkers, which face similar sensitivity limitations, a SERS-based immunosensor using AgAu@Ag triangular nanonets and Si@Au@GO substrates enables ultrasensitive simultaneous detection of FGFR3 (73.36 fg/mL) and NMP22 (21.56 fg/mL) via plasmonic coupling (enhancement factor 1.88 × 10⁸), allowing non-invasive BCa staging [110]. This dual-target FGFR3/NMP22 immunosensor further achieves high accuracy in urine, demonstrating that multiplex detection outperforms single-analyte assays for BCa diagnosis [110]. Additionally, to overcome the limited proteome coverage of urine relative to serum, nanoparticle-protein corona technology, employing Fe₃O₄@SiO₂ nanoparticles to deepen urine proteome coverage, coupled with proteomic transfer learning (ProteoTransNet), integrated serum and urine biomarkers to achieve an AUC of 0.996 for diagnostic classification, significantly outperforming conventional methods (Fig. 3B) [111]. These nanotechnology-driven approaches address key challenges in specificity, sensitivity, and multiplexity, offering promising pathways for non-invasive BCa monitoring and early detection. Nanoprobes for in vitro cellular imaging and analysis Conventional cellular imaging modalities remain constrained by intrinsic trade-offs, including photobleaching, limited penetration depth, and inadequate molecular specificity, thereby limiting comprehensive single-cell characterization of BCa biology. Nanoprobes represent a transformative tool for advanced in vitro cellular imaging and analysis, enabling comprehensive, high-content investigation of BCa biology at the single-cell level. By integrating multiple contrast mechanisms, such as fluorescence, SERS, MRI, and photoacoustic signals, within a single nanoplatform, these probes overcome the limitations of unitary imaging modalities, such as photobleaching, low penetration depth, or lack of molecular specificity. For instance, quantum dot–gold nanoparticle hybrids allow simultaneous fluorescence-based tracking and SERS-based molecular profiling, while iron oxide–dye composites enable correlative MRI and confocal microscopy (Fig. 4). Multimodal nanoprobes for in vitro imaging and functional analysis of bladder cancer cells. A. Nanoprobe construction. Multifunctional nanoprobes are built on a core nanocarrier integrated with targeting ligands, multimodal imaging components (e.g., fluorescence, SERS, MRI, or photoacoustic probes), and therapeutic cargos, enabling modular and unified functional design. B. Specificity and imaging. The combination of complementary imaging modalities allows selective recognition and dynamic tracking of bladder cancer cells, providing high-resolution visualization of cell–matrix interactions and anatomical discrimination of invasive phenotypes. C. Therapy monitoring. Multimodal nanoprobes enable real-time assessment of intracellular uptake, distribution, and therapeutic response through functional readouts such as reactive oxygen species generation, mitochondrial dysfunction, and immunogenic cell death, supporting quantitative evaluation of treatment efficacy. Created with BioRender.com Multimodal imaging for the specific identification and tracking of BCa cells Precise identification and tracking of BCa cells are hampered by poor bladder mucosal penetration, lack of molecular specificity, and difficulty in distinguishing muscle-invasive from non-muscle-invasive subtypes using single-modality imaging. Multimodal imaging platforms, particularly those integrating fluorescence imaging (FI) with magnetic resonance imaging (MRI) or photoacoustic imaging (PAI), have significantly advanced the precision of BCa cell identification and tracking.Dual-modal FI/PAI systems leveraging second NIR-II window probes, such as fluorinated albumin nanocages, enable high-resolution visualization of tumor margins and stromal interactions by concurrently targeting cancer-associated fibroblasts (CAFs) and tumor cells via SPARC protein recognition [112]. Beyond molecular imaging strategies, multiparametric MRI-based VI-RADS scoring has emerged as a clinically relevant tool for evaluating treatment response in muscle-invasive bladder cancer. Notably, recent evidence demonstrates that post-treatment VI-RADS scores can effectively assess response to neoadjuvant immunotherapy, supporting its potential as a non-invasive imaging biomarker for therapeutic stratification [113]. In BCa cell lines (e.g., T24), studies demonstrate that FI/PAI-guided approaches using riboflavin-functionalized nanoparticles RFA@DHA NPs improve target-to-background ratios by 3.1-fold under UV irradiation, facilitating real-time tracking of cellular uptake and ROS-induced apoptosis via mitochondrial membrane potential disruption [114]. Furthermore, to monitor dynamic changes in the tumor immune microenvironment, copper-based hybrid nanozymes (CuSR4M) synergize FI with MRI-sensitive components to monitor chemokine modulation (e.g., CCL5) and PD-L1 expression dynamics, correlating with immune cell infiltration in orthotopic models (Fig. 3C) [115]. These systems not only enhance diagnostic accuracy but also theranostic potential by validating target engagement through quantifiable metrics like signal persistence and heterogenicity indices. Nanoprobe for drug uptake monitor Real-time tracking of drug uptake, distribution, and therapeutic efficacy at the cellular level remains largely inaccessible in BCa therapy, thereby constraining treatment optimization and the evaluation of drug resistance. Nanoprobes also used for monitoring drug uptake, distribution, and therapeutic efficacy at the cellular level has emerged as a transformative approach in BCa management [116]. To enable precise tracking of immunogenic cell death and T-cell infiltration, fluorinated albumin nanocages dually targeting cancer-associated fibroblasts (CAFs) and tumor cells demonstrate enhanced transmucosal drug delivery, facilitating precise tracking of immunogenic cell death (ICD) and T-cell infiltration via SPARC-mediated uptake [112]. Further expanding this paradigm to address the need for non-invasive navigation of photodynamic therapy dosing, X-ray-activated nanotransducers with core–shell–shell structures (Ce³⁺/Tb³⁺/Nd³⁺-doped NaGdF₄) achieve NIR-II imaging-navigated fractionated photodynamic therapy. These nanoprobes, functionalized with cRGD peptides and rose bengal, allow non-invasive tracking of tumor accumulation and customized radiation dosing, achieving 100% survival in murine models via optimized intracellular ROS generation (Fig. 3D) [10]. Collectively, these nanotechnology-enabled strategies provide unprecedented resolution in visualizing intracellular drug trafficking and evaluating therapeutic synergy, underscoring their potential for optimizing precision oncology in BCa (Fig. 4). Therapeutic applications Nanocarrier-based drug delivery for intravesical chemotherapy in BCa Local intravesical therapy for NMIBC faces significant challenges, including poor drug permeability across the bladder urothelium, rapid clearance due to periodic voiding, and dose-limiting systemic toxicity [117, 118]. Nanocarrier systems have emerged as a promising strategy to overcome these limitations by enhancing tumor-specific targeting, prolonging drug retention, and improving cellular uptake while minimizing adverse effects (Table 3). At an early age, to address the need for synergistic co-delivery of chemotherapeutics at optimal ratios, a solvent displacement method was employed to ratiometrically incorporate dioleoyl phosphatidic acid (DOPA)-gemcitabine monophosphate and DOPA-coated cisplatin-precipitate nanocores into the PLGA-PEG-Anisamide nanoparticles (PLGA NPs) [119]. The gemcitabine and cisplatin derivatives were incorporated at an optimal synergistic molar ratio of 5:1, achieving high encapsulation efficiency exceeding 70%. Critically, these NPs facilitated ratiometric cellular uptake, a feature preserved in both in vitro and in vivo models [119]. This strategic co-delivery translated into potent synergistic anti-cancer activity within a challenging, stroma-rich bladder tumor model, where a single injection of the dual-drug NPs significantly suppressed tumor growth [119]. However, such early nanocarriers primarily focused on drug co-delivery and lacked optimization for bladder-specific retention and mucosal interaction. To address these limitations, mucoadhesive nanoplatforms based on hyperbranched polyglycerols (HPGs) were developed, significantly enhancing intravesical retention and tissue penetration. These HPG-C(8/10)-MePEG-NH₂ nanoparticles, featuring a hydrophobic C₈/C₁₀ alkyl core and a shell functionalized with methyl PEG and amine groups, were synthesized and loaded with docetaxel (DTX) via solvent evaporation [120, 121]. The mucoadhesive properties of this formulation markedly enhanced drug retention and uptake in murine bladder tissue. Furthermore, studies with rhodamine-labeled nanoparticles confirmed their superior penetration into tumor tissue [121]. Importantly, intravesical instillation of DTX in these HPG formulations (at concentrations up to 1.0 mg/mL) proved exceptionally well-tolerated, showing no signs of local or systemic toxicity in an orthotopic BCa model and matching the safety profile of commercial DTX formulations [120, 121]. In addition, to further improve intravesical retention and tumor targeting, biomimetic strategies have been introduced to further improve intravesical retention and tumor targeting. A recent study reported R11-modified tumor cell membrane nanovesicle-camouflaged nanoparticles, which combine homologous tumor targeting with mucus-penetrating capability. By integrating tumor cell membrane-derived adhesion molecules with R11-mediated penetration, this system significantly enhanced nanoparticle transport across the bladder mucus barrier and improved tumor-specific accumulation (Fig. 5A) [97]. However, these systems primarily rely on passive retention and lack active targeting capability. To overcome this limitation, a notable innovation is the development of bacteria-mediated nanocarriers, where BCG serves as a biological vector for chemotherapeutic delivery. Using the biotin-streptavidin system, live BCG was combined with drug nanoparticles for the first time. DOX-loaded PLGA nanoparticles were prepared via ultrasonic emulsification and surface-modified with streptavidin (SA-NPs) [122]. BCG was biotinylated using antibodies (B-Anti-MT), then mixed with SA-NPs to form Drugs@BCG [122]. This complex enhanced bladder DOX retention, reduced systemic toxicity, and inhibited tumor progression in orthotopic BCa models [122]. Table 3Nanocarrier platforms for enhanced intravesical chemotherapy in bladder cancerNanocarrier platform/strategyCore design & compositionTargeting/Stimuli-response mechanismKey biological/Clinical challenge addressedDemonstrated outcome & advantageCo-delivery polymeric nanoparticles [119]PLGA-PEG-Anisamide NPs ratiometrically loaded with DOPA-Gemcitabine & DOPA-Cisplatin nanocoresAnisamide ligand for receptor-mediated targetingOvercoming drug resistance via synergistic gemcitabine/cisplatin (5:1 ratio) delivery in stroma-rich tumorsRatiometric cellular uptake preserved in vivo; significant tumor growth suppression with a single doseMucoadhesive hyperbranched polyglycerols (HPGs) [120, 121]HPG-C (8/10)-MePEG-NH₂ nanoparticles with hydrophobic core, loaded with Docetaxel (DTX)Mucoadhesive surface prolongs contact with bladder urotheliumEnhancing drug retention and penetration despite periodic urine voidingSuperior tumor tissue penetration; excellent local tolerance at high concentrationBacteria-mediated delivery (BCG Vector) [122]Streptavidin-modified PLGA nanoparticles (SA-NPs) loaded with Doxorubicin (DOX), conjugated to biotinylated BCGBCG as a biological vector for bladder adhesion and internalizationImproving localized drug delivery and retention while leveraging immunostimulatory properties of BCGEnhanced bladder DOX retention, reduced systemic toxicity, and inhibited tumor progression in orthotopic modelsStimuli-responsive prodrug nanoparticlesGSH-sensitive copolymer (PHHM) conjugated with WEE1 inhibitor (MK1775) and co-assembled with Pt (IV) prodrug [123]Intracellular GSH triggers drug release.Overcoming cisplatin resistance (via WEE1 inhibition) and immunosuppressive TME.Preferential tumor accumulation, minimized systemic toxicityPoly (OEGMA)-PTX prodrug (GFLG linker) loaded with Ce6 [124]Cathepsin B enzyme cleaves GFLG linker for PTX release; Ce6 for PDT.Combining chemotherapy with PDT.Effective antitumor effect in patient-derived xenograft (PDX) modelsCoordination-assembled nanoplatform (CAN) for sonochemotherapy [125]Fluorinated nanoparticles with reversible Schiff base bonds, integrating hypoxia-activatable CPT prodrugUltrasound-triggered ROS generation and hypoxia-activated drug releaseSpatiotemporally controlled drug release concurrent with sonodynamic therapy (SDT)Enhanced tumor penetration and oxygen availability; mitigated SDT-aggravated hypoxia and off-target toxicityTight junction modulating nanoparticles [126]PEGylated Fluorinated Chitosan nanoparticles (PGFCS NPs) with surface aldehyde groups.Selective tumor adhesion and reversible upregulation of pMLC to disrupt epithelial tight junctions.Achieving tumor-specific enhancement of drug permeability across the urothelium.Enhanced targeted delivery of therapeutics (e.g., THP, IL-12) in orthotopic and PDX models, improving chemo-immunotherapy.Urease-Driven biomimetic nanorobot [195]siRNA-loaded outer membrane vesicles (OMVs) surface-modified with urease enzyme (OMV-siR robot).Urease catalyzes urea to generate autonomous thrust; Cell-penetrating peptide (CPP) enhances cellular uptake.Enhancing penetration and intracellular delivery efficiency of nucleic acid drugs within bladder tumor tissue.Effective propulsion significantly improved tumor targeting and tissue penetration, boosting gene silencing efficacy in an orthotopic bladder tumor model.Cancer cell membrane-coated Co-delivery system [208]Calcium carbonate nanoparticles co-loaded with miR-451 and adriamycin, coated with cancer cell membrane (MCC/R-A).Cancer cell membrane mediates homotypic tumor targeting; Calcium carbonate decomposes in the acidic tumor microenvironment.Addressing multidrug resistance and achieving synergistic targeted delivery of chemotherapeutic and gene drugs.Specific binding to drug-resistant cells via membrane-mediated homing effect increased drug retention and demonstrated favorable anticancer outcomes. Nanocarrier platforms for enhanced intravesical chemotherapy in bladder cancer Representative nanotechnology-based strategies in bladder cancer therapy. A. Penetration efficiency of R11@TM@PLGA-G in tumor spheroids.Reproduced with permission from ref. [97], copyright 2022 Elsevier. B. The flow cytometry (left insets) and the fluorescence analysis (right insets) of ROS-generation by ICG@R11-CeO2 in T24/253J cells. Reproduced with permission from ref. [11], copyright 2025 Springer. C. Biodistribution of CuO-PEG in MB49-bearing mice. Reproduced with permission from ref. [146], copyright 2025 Springer. D. In vivo anticancer treatment NPs@Ce6 plus short-term irradiation (L) or short-long-term irradiation (SL) in human bladder cancer PDX model. Reproduced with permission from ref. [124], copyright 2021 Elsevier. E. Mucoadhesive mRNA nanoparticle-mediated delivery of KDM6A reduces the metastatic capability of bladder cancer in orthotopic mouse models. Reproduced from ref. [160] under a Creative Commons. Copyright 2022 The Author(s) To overcome cisplatin resistance and improve therapeutic specificity, recent studies have explored mechanism-driven nanoplatforms that go beyond conventional cytotoxicity. For example, Zheng et al. developed a two-pronged nanodelivery system capable of inducing SLC7A11-independent disulfidptosis, a newly identified form of programmed cell death distinct from apoptosis and ferroptosis [96]. Importantly, this study highlights a shift from drug delivery optimization toward mechanism-oriented therapeutic reprogramming, addressing the limitation of traditional nanocarriers that rely solely on enhanced drug accumulation without overcoming resistance pathways [96]. Cisplatin resistance in BCa often arises from enhanced DNA repair capacity, while the immunosuppressive tumor microenvironment limits the efficacy of immune checkpoint blockers (ICBs). To address these dual challenges, a glutathione (GSH)-sensitive copolymer (PHHM) was synthesized and conjugated with MK1775, a selective WEE1 inhibitor, to form PHHM-MK1775123. This conjugate co-assembled with a hydrophobic cisplatin prodrug (Pt(IV)) into nanoparticles (NP2), which, upon intravenous administration, accumulated preferentially in tumors and minimized off-target toxicity [123]. Another research effort aimed to achieve spatiotemporally controlled drug release and enhanced cellular uptake by developing a stimuli-responsive, amphiphilic block poly (OEGMA)- PTX prodrug loaded with Ce6124. The hydrophilic fragment of the polymer prodrug was synthesized via reversible addition-fragmentation chain transfer polymerization of OEGMA, with the anti-tumor drug PTX covalently linked to the polymer backbone through a cathepsin B-responsive tetrapeptide Gly-Phe-Leu-Gly (GFLG) [124]. This self-assembled nanostructure efficiently encapsulated Ce6 for PDT and photochemical internalization and exhibited antitumor effect in a BCa patient-derived tumor xenografts (PDXs) model [124]. Compared with earlier delivery systems, these approaches introduce programmable responsiveness, enabling spatiotemporal control of drug activation and improved therapeutic precision. Sonochemotherapy (SCT) has emerged as a promising cancer treatment modality through ultrasound-triggered excessive ROS generation and controlled chemotherapeutic drug release. However, achieving spatiotemporally controlled drug release concurrent with ROS production remains a significant challenge. An innovative study introduces a coordination-assembled nanoplatform (CAN) system integrating reversible covalent Schiff base bonds with hypoxia-activatable camptothecin (CPT) prodrugs [125]. The self-assembled fluorinated CAN nanoparticles formed in aqueous solution confer deep tumor penetration and cytosolic delivery capabilities by enhancing polymer affinity toward both cellular membranes and endo/lysosomal membranes during intravenous administration [125]. Subsequently, CAN nanoparticles elevate intratumoral oxygen availability to potentiate ultrasound-triggered ROS generation, thereby augmenting hypoxia-activated CPT release and ultimately enhancing sonodynamic therapy (SDT) efficacy against BCa [125]. Building on this mechanism, the CAN system achieves effective tumor-targeted delivery and antitumor outcomes [125]. Relative to free CPT, CAN significantly mitigates adverse effects exacerbated by SDT-aggravated tumor hypoxia and reduces bladder-specific toxicity while enabling precise CPT release activation [125]. Although current strategies aim to improve intravesical drug penetration, they often lack the specificity to distinguish malignant from healthy urothelium. Perfluoroheptanoic acid and PEG-COOH1k were conjugated to chitosan amino groups via fluorophilic self-assembly, forming PEGylated FCS nanoparticles (PFCS NPs) [126]. Subsequent Schiff-base reaction between glutaraldehyde and residual amino groups functionalized PFCS NPs with surface aldehyde groups, yielding PGFCS NPs and PEG modification improved reaction controllability and inhibited CS crosslinking through steric hindrance [126]. Within PGFCS, the FCS framework mediated bladder epithelial tight junction regulation by upregulating pMLC expression, consequently inducing cytoskeletal rearrangement and TEER reduction [126]. In orthotopic mouse and human PDX bladder tumor models, PGFCS pretreatment enhanced tumor-targeted delivery of intravesical THP and IL-12 through selective tumor adhesion and reversible tight junction modulation, improving chemoimmunotherapy efficacy [126]. Overall, intravesical nanocarrier systems represent the most clinically advanced nanotechnology-based strategy for BCa, as they directly address key physiological barriers, particularly rapid drug dilution and limited bladder residence time. Among these, mucoadhesive and stimuli-responsive nanoplatforms show the greatest translational potential by enhancing urothelial retention and enabling controlled drug release. Notably, hyperbranched polyglycerol (HPG)-based nanoparticles demonstrate a favorable safety profile with minimal local and systemic toxicity, together with improved tumor penetration and intravesical retention in preclinical models. In parallel, bacteria-mediated nanocarrier systems, such as BCG-based hybrids, offer a unique advantage by integrating chemotherapy with established immunotherapy, thereby enabling synergistic therapeutic effects. Despite these advances, several key challenges remain for clinical translation. First, the structural complexity of multifunctional nanocarriers raises concerns regarding batch-to-batch reproducibility and large-scale manufacturing. Second, heterogeneous tumor architecture, particularly in large or multifocal lesions, limits uniform nanoparticle penetration and therapeutic efficacy. Third, the lack of standardized intravesical administration protocols introduces variability in treatment outcomes. Finally, insufficient data on long-term bladder toxicity and systemic absorption hinder clinical evaluation. Future studies should prioritize clinically translatable formulations with robust preclinical validation, particularly HPG-based docetaxel delivery systems and BCG-mediated nanocarrier platforms, which currently show the most consistent efficacy and safety profiles. Nanophotosensitizer-mediated photodynamic therapy Traditional photodynamic therapy (PDT) for BCa is hampered by the inherent limitations of molecular photosensitizers (PSs), including poor water solubility, low tumor selectivity, rapid clearance, and inadequate reactive oxygen species (ROS) generation efficiency [11]. By encapsulating hydrophobic PSs such as Chlorin e6 or Protoporphyrin IX within polymeric nanoparticles, liposomes, or inorganic carriers, nano-formulations significantly enhance PS solubility, stability, and circulation time [127] (Table 4). Table 4Nanophotosensitizer platforms for enhanced photodynamic therapy in bladder cancerNanoplatform category & exampleCore design & compositionWorking/Activation mechanismKey design features & performance metricsTherapeutic outcome & advantageMucoadhesive & O₂-generating nanozymeICG@R11-CeO₂ [208]Indocyanine green (ICG) conjugated with R11 peptide-modified cerium oxide nanoparticles.• Penetration: R11 peptide enhances mucosal adhesion and penetration.• O₂ Supply: CeO₂ nanozyme catalytically decomposes tumor H₂O₂ to O₂.• PDT: ICG generates singlet oxygen.• Mucosal penetration depth: 178.7 μm.• Singlet oxygen yield increased 3.52-fold vs. free ICG.Alleviates tumor hypoxia; significantly boosts PDT efficacy in the hypoxic tumor microenvironment.NIR-activated upconversion platformUCNP@mSiO₂/ZnPc [128]NaYF₄ UCNPs coated with mSiO₂ and loaded with zinc phthalocyanine (ZnPc).• Light Conversion: 980 nm NIR light is upconverted to visible wavelengths.• Activation: Upconverted light activates the ZnPc photosensitizer.• Excellent aqueous stability and concentration-dependent cellular uptake.• Enables deep-tissue activation with NIR light.Achieves deep-tissue PDT; overcomes limited penetration of visible light, minimizing damage to healthy tissue.Mineral-Doped & ROS-Amplifying NPs [114]RFA@DHA NPs [114]Riboflavin (RFA) decorated on dual-mineral (Ce/Zn) doped hydroxyapatite nanoparticles (DHA).• Activation: UV irradiation.• Mechanism: Generates ROS and disrupts mitochondrial membrane potential.• IC₅₀ of 27.9 µg/mL in T24 cells.• ROS production increased 3.1-fold.Induces potent mitochondrial-mediated apoptosis; offers a mineral-based, biocompatible platform for ROS amplification.Multimodal image-guided LNPsPPBC LNPs [130]LNP encapsulating a pyropheophorbide a-bisaminoquinoline conjugate (PPBC) via microfluidics.• Imaging: Inherent fluorescence (FL) and photoacoustic (PA) signals.• Therapy: Generates ROS under light irradiation for PDT.• Size: ~107 nm; PDI: 0.15.• Encapsulation efficiency > 98%; stable for 6 weeks.• Integrates FL/PA imaging directly into the therapeutic agent.Enables precise image-guided therapy; simplifies formulation by combining diagnosis and therapy in a single agent.Nanocarbon-Based Hybrid PS CarrierZn-TMPyP@GQDs [131]Graphene oxide quantum dots (GQDs) non-covalently loaded with zinc porphyrin photosensitizers (Zn-TMPyP).• Carrier Function: GQDs efficiently load and deliver hydrophobic PSs.• PDT: PS generates ROS upon light activation.• PS performance preserved after immobilization.• Induces lysosome-mediated apoptosis.Prevents PS self-quenching and aggregation; enhances targeted delivery and maintains high photodynamic activity.X-Ray-Activated Deep-Penetration SystemNaGdF₄:Ce/Tb@Nd@NaLuF₄ [10]Core-shell-shell upconversion nanostructure doped with lanthanide ions (Ce³⁺/Tb³⁺/Nd³⁺), surface-functionalized with rose bengal.• Activation: X-rays induce radiochemiluminescence in the nanotransducer.• Energy Transfer: Luminescence activates the surface rose bengal for PDT.• Activated by deeply penetrating X-rays.• Enables non-invasive NIR-II imaging guidance.Overcomes all optical penetration limits; allows for fractionated, image-guided PDT deep within tissue with minimal skin phototoxicity. Nanophotosensitizer platforms for enhanced photodynamic therapy in bladder cancer Mucoadhesive & O₂-generating nanozyme ICG@R11-CeO₂ [208] • Penetration: R11 peptide enhances mucosal adhesion and penetration. • O₂ Supply: CeO₂ nanozyme catalytically decomposes tumor H₂O₂ to O₂. • PDT: ICG generates singlet oxygen. • Mucosal penetration depth: 178.7 μm. • Singlet oxygen yield increased 3.52-fold vs. free ICG. NIR-activated upconversion platform UCNP@mSiO₂/ZnPc [128] • Light Conversion: 980 nm NIR light is upconverted to visible wavelengths. • Activation: Upconverted light activates the ZnPc photosensitizer. • Excellent aqueous stability and concentration-dependent cellular uptake. • Enables deep-tissue activation with NIR light. Mineral-Doped & ROS-Amplifying NPs [114] RFA@DHA NPs [114] • Activation: UV irradiation. • Mechanism: Generates ROS and disrupts mitochondrial membrane potential. • IC₅₀ of 27.9 µg/mL in T24 cells. • ROS production increased 3.1-fold. Multimodal image-guided LNPs PPBC LNPs [130] • Imaging: Inherent fluorescence (FL) and photoacoustic (PA) signals. • Therapy: Generates ROS under light irradiation for PDT. • Size: ~107 nm; PDI: 0.15. • Encapsulation efficiency > 98%; stable for 6 weeks. • Integrates FL/PA imaging directly into the therapeutic agent. Nanocarbon-Based Hybrid PS Carrier Zn-TMPyP@GQDs [131] • Carrier Function: GQDs efficiently load and deliver hydrophobic PSs. • PDT: PS generates ROS upon light activation. • PS performance preserved after immobilization. • Induces lysosome-mediated apoptosis. X-Ray-Activated Deep-Penetration System NaGdF₄:Ce/Tb@Nd@NaLuF₄ [10] • Activation: X-rays induce radiochemiluminescence in the nanotransducer. • Energy Transfer: Luminescence activates the surface rose bengal for PDT. • Activated by deeply penetrating X-rays. • Enables non-invasive NIR-II imaging guidance. The development of nano-photosensitizers (nano-PSs) that intrinsically promote oxygen generation represents an important strategy to overcome tumor hypoxia and improve the effectiveness of PDT. A mucosa-adhesive nanozyme (ICG@R11-CeO₂) was engineered by conjugating indocyanine green (ICG) with R11 polypeptide-modified cerium oxide nanoparticles. This system demonstrated dual functionality, it penetrated the mucosal barrier with a depth of 178.7 μm and alleviated tumor hypoxia by catalytically decomposing H₂O₂ to oxygen, thereby boosting singlet oxygen yield by 3.52-fold compared to free ICG (Fig. 5B) [11]. To enable deep-tissue NIR-triggered PDT while avoiding UV-associated toxicity, mesoporous silica-coated sodium yttrium fluoride UCNPs loaded with zinc phthalocyanine photosensitizers exhibit excellent aqueous stability and concentration-dependent cellular uptake in MB49 BCa cells [128]. Upon 980 nm NIR irradiation, these nanoplatforms efficiently generate cytotoxic singlet oxygen, as validated through multiple assays including viability testing and confocal microscopy, demonstrating their significant potential for NIR-triggered PDT in BCa treatment [128]. In another study aimed at improving ROS generation and mitochondrial targeting, riboflavin-decorated dual-mineral (Ce/Zn) doped hydroxyapatite nanoparticles (RFA@DHA NPs) achieved an IC₅₀ of 27.9 µg/mL under UV irradiation in T24 BCa cells, attributed to a 3.1-fold increase in ROS production and mitochondrial membrane potential disruption [129]. To integrate imaging and therapy within a single agent without additional dyes, Tang et al. introduced pyropheophorbide a-bisaminoquinoline conjugate lipid nanoparticles PPBC LNPs as a bimodal system for image-guided phototherapy in BCa [130]. Formulated via microfluidics, PPBC LNPs exhibit excellent biocompatibility and stability, possessing an average size of 107 nm, spherical morphology, narrow size distribution (PDI 0.15), and near-neutral charge (1.72 mV). Encapsulation efficiency exceeds 98%, with the reconstituted form retaining stability for 6 weeks at +4 °C. PPBC LNPs retain the optical properties of PPA for fluorescence (FL) imaging and their photoacoustic (PA) signal aligns with their NIR absorption, enabling effective PA contrast. This integrates PA and FL imaging directly within the therapeutic agent, eliminating the need for additional dyes. In an orthotopic BCa model, PPBC LNPs specifically accumulated at tumor sites. Therapy generated ROS, correlating with increased deoxyhemoglobin signals indicating oxygen consumption for effective PDT. This integrated approach simplifies formulation, reduces potential toxicity, and ensures consistent pharmacokinetics [130]. To mitigate photosensitizer aggregation and the consequent reduction in efficacy following immobilization, graphene oxide and quantum dots (GQDs) enable efficient non-covalent loading of porphyrinic photosensitizers (TMPyP, Zn-TMPyP, P1-C5) for precision BCa PDT [131]. Photosensitizer performance remains uncompromised post-immobilization, with wavelength-dependent efficacy, TMPyP/Zn-TMPyP show superior activity under blue light compared to P1-C5 under red light [131]. Zn-TMPyP@GQDs emerge as the optimal hybrid, inducing lysosome-mediated apoptosis through enhanced ROS generation, preventing therapeutic compromise while advancing targeted PDT [131]. Moreover, the limited tissue penetration of visible light has prompted the development of approaches that enable fractionated PDT with minimal skin phototoxicity. For instance, X-ray-activated nanotransducers with core–shell–shell structures (e.g., NaGdF₄:Ce³⁺/Tb³⁺@Nd³⁺@NaLuF₄) enabled non-invasive NIR-II imaging and generated radiochemiluminescence to activate rose bengal, facilitating fractionated PDT with minimal skin phototoxicity in orthotopic BCa models [10]. These nanoplatforms address key limitations of conventional PDT by enhancing tumor-selective accumulation through surface functionalization and leveraging nanozyme activities to modulate the tumor microenvironment [132]. Collectively, nanophotosensitizer-based PDT improves tumor selectivity, ROS generation, and imaging-guided precision compared with conventional PDT. Hypoxia-modulating and multimodal imaging-integrated strategies further enhance therapeutic efficacy. However, limited light penetration, heterogeneous oxygen distribution, and potential phototoxicity still restrict clinical application, particularly in advanced lesions. X-ray-activated nanotransducers represent the most promising approach for clinical translation, as they overcome light penetration limits and enable deep-tissue PDT. NaGdF₄-based core–shell systems have achieved complete tumor suppression with 100% survival in orthotopic models, while mucoadhesive nanozymes (e.g., ICG@R11-CeO₂) improve hypoxia and mucosal penetration. Key challenges include long-term biosafety of lanthanide materials, complexity of X-ray dosimetry, variability in tumor oxygenation, and regulatory barriers for device–drug combinations. With these issues addressed, X-ray-activated PDT is likely to advance toward early clinical evaluation within the next few years. Nanomaterial-mediated photothermal therapy Nanomaterial-mediated photothermal therapy (nano-PTT) has emerged as a highly localized and minimally invasive modality for cancer treatment [133]. This strategy leverages the unique properties of photothermal agents (PTAs) that efficiently absorb light energy, typically from near-infrared (NIR-I, 750–900 nm; or NIR-II, 1000–1350 nm) light, and convert it into localized heat [134–136]. The use of NIR light is critical due to its superior tissue penetration depth compared to visible light, enabling the treatment of non-superficial lesions. The resultant hyperthermia (typically > 42 °C) induces rapid protein denaturation and irreversible damage to tumor cells, leading to coagulative necrosis and effective tumor ablation while sparing surrounding healthy tissue [135, 137, 138] (Table 5). Table 5Nanomaterial platforms for photothermal therapy in bladder cancerNanoplatform & categoryCore design & CompositionWorking/Imaging mechanismKey therapeutic functionTherapeutic outcome & advantageTunable gold nanostructures [138]Gold Hollow Nanorods (AuHNRs) modified with quaternized chitosan (HTCC).• PTT: NIR-II light absorption and heat conversion.• Drug Release: Heat triggers decomposition of co-loaded ammonium bicarbonate for burst release.• Enhanced mucosal penetration.• Heat-triggered, controlled drug release.• 144% increase in bladder mucosal permeability.• 2.79-fold drug release boost within 1-h post-irradiation.Photosynthetic Bio-hybrid [209]Chlorella microalgae integrated with nanoparticles (GCS-IO NPs).• PTT: NIR (808 nm) irradiation induces hyperthermia.• Oxygenation: Photosynthesis (660 nm light) generates O₂.• Ferroptosis: Iron oxide component induces ferroptosis.• Alleviates tumor hypoxia.• Synergistic PTT & ferroptosis.• Achieves > 50 °C hyperthermia.• 82% tumor volume reduction in murine models via multi-mechanism synergy.NIR-II Imaging-Guided PTA [139]HAPO-1048 nanoparticles (example).• Imaging: Provides NIR-II photoacoustic imaging (PAI).• PTT: Serves as a photothermal agent.• Deep-tissue, real-time imaging with high contrast.• Precise tumor ablation.• Deeper penetration & higher signal-to-noise ratio than NIR-I PAI.• Enables precise ablation of small (~2 mm) early-stage tumors.Immunomodulatory LNPs [140]R848/DTPA@DSPE-PEG lipid nanoparticles.• PTT: DTPA agent converts light to heat.• Immunomodulation: R848 adjuvant promotes M1 macrophage polarization.• Therapy: Heat and ROS induce immunogenic cell death (ICD).• Combines tumor ablation with immune microenvironment remodeling.• Laser-triggered ICD and immune activation.• Inhibits tumor growth via synergistic local and systemic effects. Nanomaterial platforms for photothermal therapy in bladder cancer • PTT: NIR-II light absorption and heat conversion. • Drug Release: Heat triggers decomposition of co-loaded ammonium bicarbonate for burst release. • Enhanced mucosal penetration. • Heat-triggered, controlled drug release. • 144% increase in bladder mucosal permeability. • 2.79-fold drug release boost within 1-h post-irradiation. • PTT: NIR (808 nm) irradiation induces hyperthermia. • Oxygenation: Photosynthesis (660 nm light) generates O₂. • Ferroptosis: Iron oxide component induces ferroptosis. • Alleviates tumor hypoxia. • Synergistic PTT & ferroptosis. • Achieves > 50 °C hyperthermia. • 82% tumor volume reduction in murine models via multi-mechanism synergy. • Imaging: Provides NIR-II photoacoustic imaging (PAI). • PTT: Serves as a photothermal agent. • Deep-tissue, real-time imaging with high contrast. • Precise tumor ablation. • Deeper penetration & higher signal-to-noise ratio than NIR-I PAI. • Enables precise ablation of small (~2 mm) early-stage tumors. • PTT: DTPA agent converts light to heat. • Immunomodulation: R848 adjuvant promotes M1 macrophage polarization. • Therapy: Heat and ROS induce immunogenic cell death (ICD). • Laser-triggered ICD and immune activation. • Inhibits tumor growth via synergistic local and systemic effects. The advancement of nano-PTT hinges on the development of high-performance PTAs with strong absorption, high photothermal conversion efficiency (PCE), and good biocompatibility. Gold-based nanomaterials are exemplary, with geometries such as gold nanorods (AuNRs), nanoshells, and nanocages allowing tunable absorption peaks across the NIR spectrum. NIR-II-responsive drug release and enhanced bladder mucosal permeability were achieved using quaternized chitosan (HTCC)-modified gold hollow nanorods (AuHNRs), which exhibit efficient photothermal conversion and trigger drug release via thermal decomposition of ammonium bicarbonate. This system resulted in a 2.79-fold increase in drug release within 1 h post-irradiation and enhanced bladder mucosal permeability by 144% in orthotopic BCa models [138]. LNPs incorporating porphyrin-derived photosensitizers (e.g., PPBC) achieve integrated photodynamic and photothermal effects for synergistic therapy. Under 680–820 nm irradiation, they generate dual-mode responses, thereby inducing irreversible tumor damage [130]. In orthotopic BCa models, they achieved tumor-specific accumulation and generated ROS under irradiation, enabling simultaneous imaging and oxygen-consuming PDT without exogenous contrast agents [130]. Tumor hypoxia remains a major barrier to both photodynamic therapy and antitumor immunity, innovative platforms like photosynthetic microalgae-nanoparticle hybrids (e.g., Chlorella-GCS-IO NPs) combine NIR-driven hyperthermia (> 50 °C under 808 nm laser) with photosynthetic oxygen generation (660 nm light) to alleviate tumor hypoxia and synergize with ferroptosis induction, resulting in 82% tumor volume reduction in murine BCa models [130]. The integration of NIR-II photoacoustic imaging (PAI) with PTT further enables real-time monitoring of drug accumulation and treatment response, as seen with HAPO-1048 nanoparticles, which provided deeper tissue penetration and higher signal-to-noise ratios compared to NIR-I PAI, facilitating precise ablation of early-stage tumors as small as 2 mm139. Moreover, combining PTT with immunoadjuvants may overcome ICB challenges. One study developed biocompatible, biosafe R848/DTPA@DSPE-PEG lipid NPs for BCa therapy [140]. These NPs contain the immunostimulant R848 (promoting M1-like macrophage polarization) and the photothermal agent DTPA [140]. Laser-triggered NPs damage cancer cells, generate ROS, induce immunogenic cell death (ICD), rapidly accumulate in bladder tumors and remodel the tumor immune microenvironment to inhibit growth [140]. Nano-PTT enables rapid tumor ablation with high spatial selectivity and is particularly effective for superficial bladder lesions. Compared with PDT, its oxygen-independent mechanism provides advantages in hypoxic tumors. However, limited light penetration and the risk of off-target thermal damage restrict its application in deeper or advanced disease. Representative platforms further highlight its potential. Gold hollow nanorods (AuHNRs) with quaternized chitosan exhibit high photothermal efficiency and NIR-II responsiveness, improving mucosal permeability by up to 144%, while lipid-based systems (e.g., PPBC LNPs) enable combined photothermal-photodynamic therapy with imaging guidance. In addition, photosynthetic microalgae-nanoparticle hybrids offer a complementary strategy to alleviate tumor hypoxia. Despite these advances, key challenges remain, including limited therapeutic depth in bulky or muscle-invasive tumors, risk of collateral thermal injury to adjacent organs, lack of real-time temperature monitoring, and incomplete ablation due to heterogeneous light distribution. Among current strategies, NIR-II PTT combined with immune checkpoint blockade represents the most promising direction, as exemplified by R848/DTPA@DSPE-PEG LNPs, which remodel the tumor immune microenvironment and induce systemic antitumor immunity. Precision delivery of immunomodulators and immune activation Nanotechnology is revolutionizing BCa immunotherapy by overcoming the limitations of systemic immunomodulator delivery. BCG has been the standard of care for NMIBC, but its efficacy is limited by high recurrence rates (up to 50%) and BCG-unresponsive disease [141]. To overcome this, nanotechnology facilitates the co-delivery of BCG with synergistic agents like TLR agonists or immune checkpoint inhibitors (ICIs) (Table 6). A glutathione-responsive liposomal prodrug (LRO) enables tumor-specific oxaliplatin release and deep bladder tumor penetration, while co-delivery with BCG in chitosan gel (LRO-BCG/CS) extends intravesical retention and enhances urothelial permeability [142]. Despite the promise of cytokine-based immunotherapy, the clinical application of interleukin-12 (IL-12) remains severely limited by systemic toxicity and poor localization. To address these challenges, biomimetic nanocarriers based on EVs have been developed to enable localized and controlled cytokine delivery. A representative study employed red blood cell-derived EVs to deliver IL-12 minicircle DNA, achieving sustained intratumoral expression while minimizing systemic exposure [143]. This EV-mediated delivery system significantly enhanced local immune activation, promoting cytotoxic T cell infiltration and antitumor responses in BCa model [143]. Table 6Nanotechnology-enabled strategies for immunomodulation in bladder cancerStrategy/Immunomodulation focusRepresentative nanoplatformCore design & CompositionPrimary mechanism of immune activationKey advantage in BCa treatmentSynergistic BCG delivery [142]LRO-BCG/CS HydrogelGlutathione-responsive liposomal oxaliplatin prodrug (LRO) co-delivered with BCG in a chitosan (CS) gel.• Oxaliplatin induces immunogenic cell death (ICD).• BCG provides broad innate immune stimulation.• CS gel extends intravesical retention.Enhances urothelial permeability and tumor penetration; extends drug residence time to boost synergistic chemo-immunotherapy.Targeted immune checkpoint blockade [144]RePd@OMVs PD-L1 Biomimetic OrganellePD-L1 nanobody-engineered bacterial outer membrane vesicles (OMVs) encapsulating Re-Pd nanozymes.1. PD-L1 nanobody blocks PD-1/PD-L1 interaction.2. Re-Pd nanozymes exert POD & GSH-OXD activities to modulate ROS and redox.Achieves tumor-specific binding for precise checkpoint blockade while reshaping the immunosuppressive tumor microenvironment via nanozyme activity.STING Pathway activation [145]Urease-Powered Polymerized NPsPolydopamine nanocarriers co-loading cGAMP (STING agonist) and Mn²⁺, surface-modified with urease.1. Urease converts urinary urea into propulsion, enhancing mucosal retention.2. Mn²⁺ amplifies the cGAMP-mediated STING signaling cascade.Self-propulsion significantly improves bladder mucosal coverage and tumor penetration, enabling potent and localized innate immune activation.Metabolic modulation & Cuproptosis induction [146]CuOTeDsP NanoplatformHollow CuO nanoparticles co-loaded with terbinafine (SQLE inhibitor) and disulfiram.1. Induces cuproptosis, a novel copper-dependent cell death pathway.2. Suppresses cholesterol metabolism to downregulate PD-L1 expression.Provides a two-pronged approach: directly kills tumor cells via cuproptosis while reducing immune evasion by lowering PD-L1 levels.Personalized neoantigen mRNA vaccine (NCT03289962) [210]1mRNA-4157 (LNP) and autogene CevumeraLNPs or lipoplexes encapsulating mRNA encoding multiple patient-specific tumor neoantigens.In vivo expressed neoantigens are presented via MHC I/II pathways, activating de novo and specific CD4+/CD8 + T-cell responses.Provides fully individualized immunotherapy; persistent clonal expansion of neoantigen-specific T cells observed in clinical trials, potentially overcoming immune tolerance. Nanotechnology-enabled strategies for immunomodulation in bladder cancer • Oxaliplatin induces immunogenic cell death (ICD). • BCG provides broad innate immune stimulation. • CS gel extends intravesical retention. 1. PD-L1 nanobody blocks PD-1/PD-L1 interaction. 2. Re-Pd nanozymes exert POD & GSH-OXD activities to modulate ROS and redox. 1. Urease converts urinary urea into propulsion, enhancing mucosal retention. 2. Mn²⁺ amplifies the cGAMP-mediated STING signaling cascade. 1. Induces cuproptosis, a novel copper-dependent cell death pathway. 2. Suppresses cholesterol metabolism to downregulate PD-L1 expression. Furthermore, nanoparticles enable the localized delivery of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies), mitigating systemic immune-related adverse events while reversing T-cell exhaustion at the tumor site. A notable advancement is the development of a nanozyme-based biomimetic intelligent immune organelle. This system utilizes ROS-responsive nanocarriers co-assembled with ultra-small p-d orbital hybrid bimetallic rhenium-palladium (Re-Pd) nanozymes, which are further encapsulated by PD-L1 nanobody-engineered bacterial outer membrane vesicles (OMVs) to form RePd@OMVs PD-L1 [144]. Upon intravesical delivery, the PD-L1 nanobody specifically binds to tumor cells, effectively blocking the PD-1/PD-L1 axis to relieve T-cell suppression, while the released RePd nanozymes concurrently exhibit peroxidase-mimic (POD) and glutathione oxidase (GSH-OXD) activities [144]. Another innovative approach features self-propelled in-situ polymerized nanoparticles designed for activating the STING pathway. This platform co-loads the STING agonist cGAMP with Mn²⁺ into polydopamine-based nanocarriers surface-modified with urease. Following intravesical instillation, the urease enzyme utilizes urea in urine as a fuel to generate autonomous propulsion, markedly enhancing mucosal retention and tumor penetration [145]. Emerging nanotechnology strategies aim to modulate core metabolic and programmed cell death pathways, thereby enhancing tumor susceptibility to immunotherapy. A representative example is the CuOTeDsP nanoplatform, which is based on hollow CuO nanoparticles co-loaded with the SQLE inhibitor terbinafine and disulfiram [146]. This system effectively induces cuproptosis and concurrently suppresses cholesterol metabolism to reduce PD-L1 expression on tumor cells (Fig. 5C) [146]. These multifaceted nanotechnologies underscore a paradigm shift towards localized, targeted immune modulation that effectively addresses the challenges of drug clearance and immune resistance in the bladder, offering powerful synergistic strategies for combination immunotherapy. Immunomodulatory nanoplatforms offer a distinct advantage in BCa by reshaping the immune landscape and overcoming the intrinsically “cold” tumor phenotype. In this context, localized delivery strategies are particularly valuable, as they concentrate immune activation within the tumor while limiting systemic exposure. Nevertheless, their efficacy is often constrained by insufficient immune priming, variability in patient immune status, and the risk of immune-related adverse events. Recent advances illustrate diverse mechanistic opportunities. For instance, urease-powered self-propelled nanoparticles enable active propulsion and prolonged intravesical retention, thereby enhancing STING pathway activation and downstream immune responses. Meanwhile, the CuOTeDsP nanoplatform introduces a metabolism-driven immunotherapeutic paradigm by coupling cuproptosis induction with PD-L1 downregulation. EV-based IL-12 delivery further exemplifies a biologically compatible approach for localized cytokine modulation. Despite these innovations, translational barriers persist, including limited patient responsiveness immune heterogeneity across tumors, potential toxicity even under localized administration, and the manufacturing complexity of personalized nanoplatforms. Taken together, platforms that integrate immune activation with complementary mechanisms, such as STING stimulation or cuproptosis induction re most likely to advance toward clinical evaluation, supported by their consistent efficacy and safety profiles in orthotopic models. Nanoplatform-mediated synergistic treatment modalities The true potential of nanotechnology in BCa management is realized through engineered nanoplatforms that enable sophisticated combinatorial therapies, overcoming the limitations of monotherapeutic approaches (Tables 7). A representative strategy involves the synergistic combination of chemotherapy and photodynamic therapy. Chemotherapy-PDT combinations leverage nanocarriers to co-deliver chemotherapeutic agents and photosensitizers, enhancing synergistic efficacy. A notable example is the RGD peptide-modified platinum nanozyme platform (PTX-SS-HPPH/Pt@RGD-NP), which co-loads a glutathione-responsive prodrug (PTX-SS-HPPH) with oxygen-generating Pt nanozymes [147]. This system achieves dual chemo-photodynamic effects by enabling glutathione-triggered release of paclitaxel (PTX) and the photosensitizer HPPH, while simultaneously alleviating tumor hypoxia via catalytic decomposition of H₂O₂ to oxygen [147]. In murine T24 BCa models, this approach significantly improved tumor penetration and retention, resulting in potent tumor suppression in both subcutaneous and orthotopic models [147]. Similarly, to enhance cellular uptake and downregulate hypoxia-associated signaling, enzyme-responsive prodrug nanoparticles (e.g., poly (OEGMA)-PTX@Ce6) demonstrated a > 98% tumor inhibition rate in PDX models through a dual-stage light irradiation strategy. This system facilitates photochemical internalization (PCI), enhancing cellular uptake and synergistically activating oxidative stress pathways while downregulating hypoxia-associated signaling (Fig. 5D) [124]. Table 7Nanoplatform-mediated synergistic treatment modalities for bladder cancerSynergistic strategy categoryRepresentative nanoplatformCore design & CompositionKey synergistic mechanismExperimental model & Key efficacyChemotherapy & PDTPTX-SS-HPPH/Pt@RGD-NP [147]RGD peptide-modified NPs co-loading a GSH-responsive PTX-HPPH prodrug and Pt nanozymes.1. GSH-triggered drug release.2. Pt nanozymes catalyze H₂O₂ to O₂, alleviating hypoxia to enhance PDT.T24 subcutaneous & orthotopic models; significant tumor suppression via enhanced penetration and retention.Poly(OEGMA)-PTX@Ce6 [124]Enzyme-responsive polymeric NPs co-delivering PTX prodrug and photosensitizer Ce6.1. Photochemical internalization boosts cellular uptake.2. Synergistic oxidative stress & hypoxia signaling downregulation.Patient-derived xenograft (PDX) model; >98% tumor inhibition rate with dual-light irradiation.Light-responsive Ru-Se nanoreactor [148]Ru-Se coordinated nanoplatform for intravesical perfusion.1. Light-triggered ROS generation (PDT).2. Catalyzes endogenous H₂O₂ to O₂, mitigating hypoxia.Designed for non-invasive intravesical application; enhances PDT efficacy by modulating TME.Chemo-PDT-PTT Tri-modal TherapyBITT@BSA-DSP NPs [9]AIEgen (BITT) and cisplatin prodrug co-loaded in bovine serum albumin (BSA) NPs.1. BITT enables NIR fluorescence imaging, enhances ROS generation and photothermal conversion.2. Co-delivery of cisplatin prodrug for chemotherapy.In vitro and in vivo BCa models; allows tumor visualization and significant tumor growth suppression.PDT & PTT with ImmunomodulationGd-Ce6@SWNHs [149]Single-walled carbon nanohorns loaded with Gd³⁺ and chlorin e6 (Ce6).Sequential PDT→PTT: PDT upregulates IFN-γ/CD80; PTT stimulates IL-6/TNF-α secretion from DCs, activating systemic immunity.Murine model; suppresses distant metastases and establishes long-term immunological memory.Multimodal Therapy (CDT/PDT/PTT)Cu₂(OH)PO₄@PAA NPs [127]Copper-based nanoparticles with photoacoustic imaging capability.1. Cu⁺-mediated Fenton-like reaction (CDT) and GSH depletion.2. NIR-triggered PDT & PTT.Integrated theranostic platform; induces apoptosis and suppresses epithelial-mesenchymal transition.Chemotherapy & PTTIR780-Alginate/Cisplatin NPs [151]Mitochondria-targeted NPs functionalized with IR780 iodide and alginate, loaded with cisplatin.1. NIR-triggered hyperthermia and triggers drug release.2. Hyperthermia enhances tumor penetration and induces mitochondrial damage.Muscle-invasive bladder cancer (MIBC) model; real-time imaging & irreversible apoptosis.Gene Therapy & ChemotherapyFeSiNTs-siSPAG5 [152]Fe-doped chrysotile nanotubes (FeSiNTs) loaded with siRNA targeting the SPAG5 oncogene.Nanotube-mediated siRNA delivery inhibits the SPAG5 oncogene, synergizing with chemotherapy.Significantly inhibited tumor growth and metastasis in an orthotopic bladder cancer model.PDA–CDDP/miRNA complexes [211]Polydopamine (PDA) nanoparticles co-loading cisplatin (CDDP) and miR-205-5p.Integrates the DNA-damaging capacity of cisplatin with the gene-silencing function of miR-205-5p.Yields synergistic antitumor activity.PPCat-survivin siRNA/Co-administered Cisplatin & siWnt NPs [212]Cationic liposomes co-loading paclitaxel and survivin siRNA; Cisplatin nanocore nanoparticles and siWnt lipopolyplexes administered together.1. Reverses chemotherapy-induced survivin upregulation to enhance efficacy.2. Concurrent inhibition of Wnt signaling and induction of DNA damage.Significantly inhibited tumor growth in a stroma-rich bladder cancer model at both early and late stages. Nanoplatform-mediated synergistic treatment modalities for bladder cancer 1. GSH-triggered drug release. 2. Pt nanozymes catalyze H₂O₂ to O₂, alleviating hypoxia to enhance PDT. 1. Photochemical internalization boosts cellular uptake. 2. Synergistic oxidative stress & hypoxia signaling downregulation. 1. Light-triggered ROS generation (PDT). 2. Catalyzes endogenous H₂O₂ to O₂, mitigating hypoxia. 1. BITT enables NIR fluorescence imaging, enhances ROS generation and photothermal conversion. 2. Co-delivery of cisplatin prodrug for chemotherapy. 1. Cu⁺-mediated Fenton-like reaction (CDT) and GSH depletion. 2. NIR-triggered PDT & PTT. 1. NIR-triggered hyperthermia and triggers drug release. 2. Hyperthermia enhances tumor penetration and induces mitochondrial damage. 1. Reverses chemotherapy-induced survivin upregulation to enhance efficacy. 2. Concurrent inhibition of Wnt signaling and induction of DNA damage. Integration of chemotherapy and PDT through intravesical perfusion, coupled with hypoxia alleviation, is enabled by a light-responsive Ru-Se coordinated nanoreactor was developed [148]. Upon light irradiation, it generates ROS while catalyzing the decomposition of endogenous hydrogen peroxide to produce oxygen, thereby alleviating tumor hypoxia and significantly enhancing PDT efficacy. Recently, to achieve NIR imaging-guided synergistic trimodal therapy, BSA-based biodegradable nanoplatform integrating an AIEgen (BITT) and a cisplatin prodrug enables NIR imaging–guided synergistic photodynamic/photothermal/chemotherapy, achieving efficient tumor visualization and robust BCa suppression. [9] To elicit systemic antitumor immunity and suppress distant metastases without exogenous adjuvants, Gd³⁺/chlorin e6–loaded carbon nanohorns enable sequential PDT–PTT that elicits complementary dendritic cell activation, induces systemic antitumor immunity and long-term immune memory, and suppresses distant metastases without exogenous adjuvants [149]. Cu₂(OH)PO₄@PAA nanoparticles integrate photoacoustic imaging with Cu⁺-mediated CDT (via Fenton-like reactions and GSH depletion) and NIR-triggered PDT/PTT, yielding synergistic antitumor efficacy through apoptosis induction and EMT suppression [127]. Nanotechnology-enabled co-delivery of PTT and chemotherapy exploits hyperthermia-triggered drug release and enhanced tumor penetration, as exemplified by IR780/alginate-functionalized, mitochondrial-targeted cisplatin nanoparticles that achieve efficient NIR photothermal conversion (32.7%), real-time imaging, and synergistic mitochondrial damage–driven apoptosis in MIBC [150, 151]. Multifunctional nanoplatforms that integrate chemotherapy, phototherapy, and immunotherapy provide a powerful strategy for enhancing antitumor efficacy beyond single-modality treatments. Their advantages arise from coordinated mechanisms, including ROS amplification, hypoxia modulation, and immune activation. Nevertheless, increasing system complexity introduces practical constraints, particularly in safety evaluation and scalable manufacturing. Recent designs illustrate the potential of such synergistic systems. For example, RGD-modified platinum nanozyme platforms (PTX-SS-HPPH/Pt@RGD-NP) enable combined chemotherapy and PDT with hypoxia alleviation. Similarly, BSA-based AIEgen systems (BITT@BSA-DSP) offer a biodegradable, single-component platform for NIR imaging-guided trimodal therapy. Despite these advances, several barriers limit clinical translation, including batch-to-batch variability arising from structural complexity, potential drug–drug interactions within nanocarriers, challenges in optimizing multi-agent dosing ratios, and regulatory hurdles for multifunctional combination products. From a translational perspective, simplified dual-modality systems (e.g., chemo–PDT or PTT–immunotherapy) may offer a more feasible pathway than fully integrated trimodal platforms, given their advantages in manufacturability, controllability, and regulatory approval. Nanomaterial-based platforms for nucleic acid in BCa management Efficient and safe delivery of nucleic acids (siRNA, miRNA, mRNA, and CRISPR plasmids) to target cells remains a key barrier in BCa gene therapy, owing to degradation, off-target effects, and immune activation. A diverse range of nanomaterial platforms has been developed to enable precise molecular interrogation and functional modulation of BCa–associated biomarkers, with particular emphasis on nucleic acid delivery (Table 8). Table 8Nanocarrier platforms for gene therapy in bladder cancerNanocarrier platformLoaded Nucleic acid/Target keyDesign feature/MechanismExperimental model & OutcomeSignificance/StageInorganic Nanotubes (Fe-doped Chrysotile, FeSiNTs) [152]siRNA/SPAG5 oncogeneUniform hollow tubular structure; prolongs blood half-life and increases tumor-specific uptake.Subcutaneous, orthotopic & metastatic models; inhibited growth, migration, metastasis with no significant toxicity.Versatile inorganic delivery platform.Inorganic Nanotubes (Halloysite, HNTs) [153]siRNA/RIPK4 kinaseElectrostatic loading into the lumen; timed release at neutral pH.Subcutaneous, orthotopic & metastatic models; suppressed tumor progression with no adverse effects.Biocompatible natural clay mineral carrier.Inorganic Nanotubes (Synthetic Chrysotile, SCNTs) [154]siRNA/circPRMT5Synthetic magnesium silicate nanotubes for efficient encapsulation.Subcutaneous, lung metastatic & orthotopic models; suppressed tumor progression and metastasis.Synthetic nanotubes for targeting circular RNA.Chitosan-modified PLGA NPs [155]siRNA/survivinChitosan surface engineering enhances mucoadhesion and cellular uptake.In vitro binding affinity increased 10-fold, bioactivity extended by 9 days; superior anti-proliferative effect in vivo.Demonstrated the critical role of mucoadhesive surface engineering for bladder delivery.Calcium Carbonate Nanocomposite (NPACC/CaIP6) [156]siRNA/AIB1 oncogeneInorganic composite for efficient intracellular delivery.Intratumoral injection attenuated tumor growth in vivo by downregulating the PI3K/Akt pathway.Early exploration of inorganic carriers for gene silencing.Exosomes (HEK293/MSC-derived) [157]siRNA/PLK-1 kinaseNatural vesicles loaded with siRNA via electroporation.Achieved selective gene silencing in vitro.Demonstrated the feasibility of natural vesicles as delivery carriers.Guanidine-Terminated Carbosilane Dendrimer (GCD) [159]siRNA/Nrf2 transcription factorCationic dendrimer enabling high-efficiency siRNA loading and cytosolic delivery.In vitro model: Reduced cisplatin resistance in bladder cancer cells with high Nrf2 levels, inhibited cell migration, and enhanced cisplatin-induced intracellular oxidative stress.Provides a nucleic acid interference-based combinational strategy to overcome chemoresistance.Mucoadhesive PLGA-Lipid Hybrid Nanoparticles [160]mRNA/KDM6A tumor suppressorCore-shell structure with an FDA-approved PLGA core encapsulating mRNA/lipid complexes; surface-engineered with terminally functionalized lipid-PEG (e.g., DSPE-PEG-NH₂) to optimize bladder mucosa adhesion.Orthotopic bladder cancer model: Effectively adhered to bladder tissue via intravesical instillation, enabling local mRNA delivery; demonstrated therapeutic efficacy in a Kdm6a-null orthotopic model while avoiding systemic protein expression issues and toxicity.Represents a clinically translatable, mucoadhesive nanopatform for intravesical mRNA replacement therapy, enabling localized and safe restoration of tumor suppressor function. Nanocarrier platforms for gene therapy in bladder cancer Inorganic nanotubes offer a powerful solution for efficient siRNA delivery against oncogenes and suppression of tumor metastasis. Fe-doped chrysotile nanotubes (FeSiNTs, 15–25 nm outer diameter, 7–8 nm inner diameter) enabling efficient siRNA delivery against the SPAG5 oncogene and significantly suppressing tumor growth and metastasis in orthotopic models [152]. The pH-responsive release capability of halloysite nanotubes (HNTs) provides a strategy to inhibit tumor progression across multiple models. Halloysite nanotubes (HNTs) with uniform 500-nm dimensions can be loaded via vacuum impregnation into Al‑OH‑rich lumens for pH‑responsive siRNA release; complexes with siRIPK4 inhibited tumor progression across subcutaneous, orthotopic, and metastatic models without adverse effects [153]. Synthetic chrysotile nanotubes (SCNTs) serve as a controllable alternative for delivering si-circPRMT5, effectively suppressing tumor growth and metastasis in multiple in vivo settings [154]. Beyond inorganic carriers, polymeric systems such as chitosan‑modified PLGA nanoparticles demonstrated markedly enhanced urothelial binding and prolonged siRNA bioactivity, leading to superior anti‑proliferative outcomes in BCa models [155]. Earlier investigations with amorphous calcium carbonate-based nanoparticles (NPACC/CaIP6) achieved efficient intracellular delivery and pathway downregulation, showing efficient intracellular delivery of siAIB1 and tumor growth attenuation via PI3K/Akt pathway downregulation [156]. Natural vesicular carriers, such as exosomes derived from HEK293 or mesenchymal stem cells, have been exploited for electroporation‑assisted siRNA loading, achieving selective gene silencing in vitro [157]. Liu et al. systematically evaluated adipose-derived stem cell exosomes as miRNA delivery systems for bladder cancer therapy [158]. Their results demonstrated efficient miRNA loading, high cellular uptake, and significant inhibition of tumor cell proliferation, highlighting the advantage of exosome-based delivery in preserving RNA stability and facilitating intracellular transport [158]. Additionally, cationic dendrimers like guanidine‑terminated carbosilane dendrimers (GCD) facilitated high‑efficiency siNrf2 delivery, reducing cisplatin resistance and enhancing oxidative stress in resistant BCa cells [159]. Recently, mucoadhesive hybrid nanoparticles constructed from FDA‑approved PLGA and functionalized lipid‑PEG conjugates have enabled localized intravesical mRNA delivery, effectively restoring tumor‑suppressor function in Kdm6a-null orthotopic models while avoiding systemic exposure (Fig. 5E) [160]. Together, these platforms highlight a versatile and evolving toolkit for targeted nucleic acid delivery, supporting the advancement of precision nanomedicine strategies against BCa. Nucleic acid delivery systems expand the therapeutic landscape of BCa by enabling direct modulation of otherwise “undruggable” genes and resistance pathways. Platforms with biodegradable and mucoadhesive properties are particularly suited for intravesical application, as they enhance local retention while limiting systemic exposure. However, translation remains constrained by suboptimal delivery efficiency, off-target effects, immune activation, and regulatory complexity. Emerging platforms highlight distinct advantages, such as Mucoadhesive PLGA–lipid hybrid nanoparticles and FeSiNTs and HNTs provide efficient siRNA delivery with favorable biocompatibility. In parallel, exosome-based systems offer a biologically derived solution with improved stability and reduced immunogenicity by leveraging endogenous intercellular communication pathways. Key translational barriers include inefficient endosomal escape, unintended gene silencing, immunogenicity of synthetic nucleic acids, high manufacturing costs for personalized therapies, and evolving regulatory frameworks. From a clinical perspective, intravesical mRNA delivery using mucoadhesive PLGA–lipid nanoparticles appear most likely to advance first, supported by robust preclinical efficacy and the use of clinically validated materials such as PLGA and lipid–PEG components. Multimodal theranostic synergy and efficacy evaluation Synergistic Integration of multimodal imaging Single-modality imaging techniques each capture only a fragment of bladder cancer pathology—anatomy, function, or molecular signature—leaving clinicians with an incomplete picture that can compromise staging and treatment planning. The convergence of multiple imaging modalities through nanotechnology has enabled a paradigm shift in BCa management, facilitating the integration of anatomical, functional, and molecular information for comprehensive tumor characterization [161, 162]. By cross-validating findings and providing complementary data dimensions, this synergistic approach overcomes the blind spots of individual techniques, ultimately enhancing diagnostic accuracy, treatment planning, and response monitoring [163, 164] (Table 9, Fig. 6). Table 9Nanotechnology-enabled multimodal theranostic synergy for bladder cancer managementTheranostic strategy & NanoplatformCore design & CompositionIntegrated imaging & Therapy mechanismKey synergistic function & Outcome Synergistic Multimodal Imaging Multiparametric MRI (mp-MRI) [169]Conventional Gd/iron oxide contrast agents; Investigational dual-mode probes (Fe₃O₄/Gd@BSA).Imaging Integration: T2WI (anatomy) + DWI (cellularity) + DCE-MRI (perfusion).Nanoprobe: Simultaneous T1-enhancing and T2-reducing contrast.Enhances sensitivity/specificity for discriminating MIBC from NMIBC; Investigational probes aim for complementary contrast and targeted imaging.NIR-II optical/Photoacoustic imaging platforms [139]Targeted NIR-II probes (HAPO-1048); Molecular probes (uPAR-targeting MNPR-101).Imaging Integration: NIR-II PAI (deep hemodynamics) + OCTA (microvasculature) ± targeted fluorescence.NIR-II provides superior penetration depth & SNR, enabling detection of sub-millimeter tumors and precise boundary delineation. Surveillance by Theranostic Synergy Adhesive nano-transformer (CTMF NPs) [213]CuS nanoparticles co-encapsulated with perfluoro-crown-ether and a manganese-polyphenol shell.Theranostic Mechanism: Cascade structural transformation upon TME activation.Imaging: Zero-background ¹⁹F-MRI + ratiometric PAI tracking decomposition.Therapy: Laser-triggered decomposition induces oxidative stress and cuproptosis.Imaging provides real-time visual feedback on nanoparticle localization and activation, directly validating therapeutic efficacy (e.g., cuproptosis).NIR-II AIEgen Integrated Platforms [5]NIR-II AIE luminogens with twisted D-π-A-π-D structure, often coated with hyaluronic acid (HA) for CD44 targeting.Theranostic mechanism: Single-component multifunctionality.Imaging: NIR-II FLI/PAI/PTI.Therapy: Type-I PDT + PTT.Integrates diagnostic (trimodal imaging) and therapeutic (dual phototherapy) functions into one component, enabling fiber-optic interventional guidance.Bioorthogonal Targeting MRI Probe [214]HA-coated iron oxide nanoparticles functionalized with DBCO for bioorthogonal labeling, can be loaded with ¹⁷⁷Lu.Theranostic Mechanism: Bioorthogonal tumor targeting post-intravesical instillation.Imaging/Therapy: Precise MRI localization + radiotherapy.Enables accurate MRI of NMIBC/MIBC and tumor downstaging, demonstrating potential for bladder-preserving therapy. Image-guided personalized treatment Bidirectional Perfusion NIR-II Imaging Probe (AuPd-P-FA) [176]Ultrasmall AuPd nanoprobe with thermally sensitive phase transition property.Theranostic Mechanism: Active targeting and enrichment after bladder perfusion.Imaging/Therapy Guidance: NIR-II FLI visualization; laser-triggered phase transition prolongs retention.Identifies optimal treatment window (peak enrichment at 1-h post-instillation) and extends the therapeutic timeframe.Dose-Fractionated PDT Nanoscintillator [10]Lanthanide-doped nanoscintillator activated by X-rays, emitting both visible and NIR-II light.Theranostic Mechanism: X-ray activation; NIR-II imaging quantifies tumor accumulation.Therapy: On-demand, dose-fractionated PDT based on quantitative imaging signal.Realizes “see-and-treat”, translating diagnostic signals into personalized therapeutic doses, moving beyond one-size-fits-all regimens. Nanotechnology-enabled multimodal theranostic synergy for bladder cancer management Imaging Integration: T2WI (anatomy) + DWI (cellularity) + DCE-MRI (perfusion). Nanoprobe: Simultaneous T1-enhancing and T2-reducing contrast. Theranostic Mechanism: Cascade structural transformation upon TME activation. Imaging: Zero-background ¹⁹F-MRI + ratiometric PAI tracking decomposition. Therapy: Laser-triggered decomposition induces oxidative stress and cuproptosis. Theranostic mechanism: Single-component multifunctionality. Imaging: NIR-II FLI/PAI/PTI. Therapy: Type-I PDT + PTT. Theranostic Mechanism: Bioorthogonal tumor targeting post-intravesical instillation. Imaging/Therapy: Precise MRI localization + radiotherapy. Theranostic Mechanism: Active targeting and enrichment after bladder perfusion. Imaging/Therapy Guidance: NIR-II FLI visualization; laser-triggered phase transition prolongs retention. Theranostic Mechanism: X-ray activation; NIR-II imaging quantifies tumor accumulation. Therapy: On-demand, dose-fractionated PDT based on quantitative imaging signal. Nanotechnology-enabled photodynamic (PDT), photothermal (PTT), and synergistic PDT–PTT strategies. A. PDT. Targeted nanoplatforms deliver photosensitizers to tumor cells, where light activation induces reactive oxygen species (ROS) generation; oxygen-supplying or cascade designs further enhance PDT under hypoxic conditions. B. PTT. Photothermal nanomaterials accumulate at tumor sites and convert near-infrared irradiation into localized heat, inducing thermal ablation. C. Synergistic PDT–PTT. Co-integration of photochemical and photothermal functions within a single nanoplatform enables concurrent ROS generation and hyperthermia, producing enhanced antitumor efficacy relative to monotherapies. Created with BioRender.com Accurate BCa staging demands more than what any single MRI sequence can offer alone. Multi-parameter magnetic resonance imaging (mp-MRI) exemplifies this integration by combining T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) MRI [165]. T2WI provides high-resolution anatomical details, clearly delineating the layers of the bladder wall and identifying structural disruptions caused by tumors [113, 166]. Yet T2WI struggles to differentiate tumors that are isointense to muscle. DWI fills this gap by offering functional insights into cellularity through water diffusion restrictions, where high signal intensity on DWI typically indicates high cellularity in malignant tissues. When T2WI and DWI are used together, they achieve superior sensitivity and specificity in discriminating MIBC from NMIBC compared with either sequence alone [167]. Furthermore, DCE-MRI adds microvascular information by tracking contrast agent kinetics, revealing tumor perfusion and permeability, which are hallmarks of angiogenesis [168]. It is worth noting that nanotechnology-enabled multiparametric MRI has so far been applied mainly to liver fibrosis, not BCa, representing an unexplored opportunity for BCa. For example, Ma et al. developed a dual-mode T1–T2 MRI nanoprobe (Fe₃O₄/Gd@BSA-pPB) via biomineralization, in which Fe₃O₄ and Gd components provide complementary contrast while BSA-based surface engineering enables PDGFRβ-targeted recognition of hepatic stellate cells, markedly improving early fibrosis sensitivity. By simultaneously enhancing fibrotic lesion signals (T1) and suppressing background signals (T2), this structure–function integration underscores the diagnostic advantages of dual-mode nanoprobes, yet analogous applications remain unexplored in BCa [169]. Beyond MRI, nano-enabled optical imaging is expanding BCa diagnostics toward higher spatial resolution and molecular specificity, addressing the penetration limits of visible light. NIR-II imaging integrated with photoacoustic imaging and OCTA enables real-time visualization of early tumors and microvasculature, with superior penetration depth and signal-to-noise ratio over NIR-I, as demonstrated by dynamic tracking of targeted probes (HAPO-1048) and detection of sub-millimeter lesions in orthotopic BCa models [170]. In parallel, molecularly targeted nanoprobes such as the uPAR-directed MNPR-101 further enhance boundary delineation at invasive fronts, highlighting the potential of multimodal, nano-assisted optical imaging, especially when combined with anatomical MRI to guide precision surgery and advance BCa theranostics [139]. Surveillance in bladder cancer by theranostic synergy Conventional diagnostics and therapeutics operate in separate silos, offering no real-time feedback on drug distribution or treatment efficacy—a critical shortcoming for adapting to the dynamic TME. The convergence of nanotechnology with multi-modal imaging has ushered in a paradigm of “see-and-treat” BCa theranostics, enabling real-time visualization of drug distribution, accurate assessment of tumor ablation, and timely guidance for therapeutic intervention [171, 172]. By providing spatiotemporal feedback, these integrated nanoplatforms transcend the limitations of separate diagnosis and therapy, which is crucial for adapting treatment strategies to dynamic TME (Table 9) [173]. A materials-driven theranostic strategy that combines cascade transformation, imaging, and therapy is exemplified by adhesive nano-transformers (CTMF NPs). Constructed from CuS nanoparticles co-encapsulated with perfluoro-15-crown-5-ether and a Mn–polyphenol shell, CTMF NPs undergo TME- and laser-triggered disassembly, enabling zero-background ^19F-MRI and ratiometric PA imaging while amplifying oxidative stress and inducing mitochondrial damage [174]. The on-demand release of Mn²⁺ generates T1-weighted MRI contrast, while dynamic PA signals report nanoparticle disintegration and cuproptosis in real time, providing visual validation of immunogenic cell death and tightly coupling diagnostic feedback with therapeutic action [174]. Simplifying phototheranostic systems by reducing multiple components into a single material has been achieved with a NIR-II AIEgen. Zhu et al. reported a single-component NIR-II AIEgen (OTTITQ) as an integrated phototheranostic material for BCa, enabling NIR-II fluorescence, photoacoustic and photothermal imaging, together with type-I PDT and PTT [164]. The twisted D–π–A–π–D molecular architecture, incorporating molecular rotors, strong electron acceptors, and π-bridges, promotes efficient intramolecular charge transfer, red-shifted NIR-II optical responses, and a reduced singlet–triplet energy gap, thereby enhancing intersystem crossing and phototherapeutic efficiency [164]. Furthermore, photoacoustic (PA) imaging has been enabled by material-driven nano-designs that couple biological targeting with signal amplification. Leveraging endogenous platelet recruitment for enhanced tumor accumulation, a representative example is the self-enriching nanozyme IrOx-P, which exploits P-selectin–mediated platelet recruitment to achieve enhanced tumor accumulation [173]. Interaction with the TME triggers oxygen bubble generation, markedly amplifying PA signals and enabling real-time, cavitation-enhanced visualization of nanocarrier localization and activity [173]. Fiber-optic compatibility is a critical step toward clinical translation of phototherapy. A rationally designed NIR-II AIEgen (BTO-TTQ) meets this need with high absorption, bright NIR-II emission, efficient photothermal conversion, and robust ROS generation [5]. Surface engineering with hyaluronic acid enabled CD44-targeted nanoparticle assembly, integrating the material into a trimodal imaging–guided, fiber-optic-compatible phototherapeutic platform for BCa, highlighting its translational potential [5]. Another multifunctional nanosystem combines MRI guidance, tumor microenvironment modulation, and combination therapy in one platform. A PLZ4-modified PLGA nanoplatform (PLZ4@SeD) co-encapsulating a selenium-based anticancer agent (SeD-1b) and hypoxia-modulating SPIONs was engineered for MRI-guided BCa theranostics [175]. This material integrates active tumor targeting, TME oxygenation, and imaging-enabled combination therapy within a single multifunctional nanosystem [175]. Image-guided personalized treatment A major drawback of conventional oncology is its empirical, one-size-fits-all approach to treatment timing and dosing, which fails to account for patient-to-patient variability in drug accumulation and tumor response. Intelligent imaging enabled by multimodal nanoprobes provides spatially and temporally resolved information that directly guides therapeutic activation. By tracking nanoparticle accumulation kinetics and local distribution, imaging readouts inform optimal treatment timing at peak material concentration. This intrinsic coupling of diagnostic signal generation with therapeutic control represents a materials-driven shift from empirical treatment toward data-guided, adaptive intervention (Table 9). Precise visualization of bladder tumors and prolonged intravesical retention are both achieved by a novel bidirectional perfusion-like administered system using an ultrasmall AuPd-P-FA nanoprobe for NIR-II fluorescence imaging. This system allows for precise visualization of bladder tumors, with the nanoprobe reaching maximum enrichment at 1-h post-instillation. Furthermore, upon laser irradiation, the nanoprobe’s thermally sensitive phase transition property significantly prolongs its retention time within the bladder, enabling both a more accurate diagnostic window and extending the potential time frame for effective therapeutic intervention [176]. Zero-background imaging and real-time therapeutic response monitoring are hallmarks of adhesive nano-transformers (CTMF NPs). These are engineered to enable zero-background ¹⁹F-MRI and ratiometric photoacoustic imaging for precise tumor localization [174]. Upon laser irradiation, these materials undergo programmed decomposition, amplifying oxidative stress and inducing cuproptosis, while simultaneous imaging readouts report nanoparticle activation and therapeutic response in real time [174]. Beyond defining the “when” and “where” of treatment, diagnostic imaging is also guiding the “how much”, transitioning from fixed dosing to personalized, image-guided dose fractionation [177]. A prime example is a lanthanide-doped nanoscintillator that simultaneously emits in both the visible and second NIR-II windows. A key capability of this platform is that the quantifiable signal from NIR-II imaging enables on-demand, dose-fractionated PDT. This means the light dose required for PDT can be precisely customized for each patient based on the actual accumulation of the nanoscintillator in the tumor, moving away from a one-size-fits-all approach and towards highly personalized dosing regimens [10]. Challenges and future perspectives Materials and manufacturing challenges The clinical translation of nanotechnology-enabled strategies for BCa is ultimately constrained by material-level limitations in synthesis reproducibility, structural stability, and long-term biosafety (Fig. 7). Achieving batch-to-batch consistency remains particularly challenging for multifunctional nanocarriers, as complex inorganic architectures often exhibit variability in crystallinity and surface chemistry, resulting in fluctuating photoluminescence efficiency and therapeutic performance [178], while supramolecular assemblies based on host–guest interactions are highly sensitive to environmental parameters, leading to inconsistent drug loading [179]. Material stability further limits translational feasibility, encompassing both storage integrity and in vivo persistence; polymeric nanoparticles such as PLGA undergo hydrolytic degradation with 15–30% payload loss under standard storage conditions [180], lipid formulations may exhibit phase separation [181, 182], and inorganic systems can suffer from ion leaching and interfacial transformations, exemplified by Cu²⁺ release from copper-based nanomaterials in acidic microenvironments [183]. In addition, dynamic protein corona formation can alter surface properties and targeting behavior, promoting mononuclear phagocyte system clearance [184, 185]. Biocompatibility and degradability therefore remain central considerations, as certain inorganic nanomaterials, including carbon nanotubes and rare-earth-doped upconversion nanoparticles, have been associated with oxidative stress, tissue fibrosis, and delayed renal clearance [186]. Collectively, these challenges underscore the need for biodegradable architectures, green chemistry principles, and simplified material designs to enhance safety, stability, and translational feasibility [187, 188]. Challenges and future perspectives of nanomaterial platforms for precision bladder cancer therapy. Nanotechnology-enabled strategies for bladder cancer are constrained by material reproducibility, long-term stability, biosafety, biological barriers, and clinical translation hurdles, including scalable manufacturing, cost, and regulatory complexity. Emerging solutions focus on intelligent nanotheranostic platforms that integrate imaging-guided adaptive therapy, microenvironment-responsive drug release, active microrobotic targeting, and personalized immunomodulation, supported by AI-assisted nanomaterial design, to enable safer, more effective, and clinically translatable precision treatments for BCa Translation and clinical challenges Despite significant advances in nanotechnology-enabled strategies for bladder cancer (BCa), their clinical translation remains limited by multiple interconnected challenges, including biosafety, material reproducibility, regulatory complexity, and large-scale manufacturing constraints (Fig. 7). In particular, the long-term fate of nanomaterials, including their biodegradability, potential accumulation, and immunogenicity, remains insufficiently understood, raising concerns regarding chronic toxicity and off-target effects. Furthermore, the structural complexity of multifunctional nanoplatforms often introduces batch-to-batch variability, which complicates standardization and regulatory approval. In addition to these material and regulatory barriers, a critical yet often underappreciated limitation lies in the preclinical models used to evaluate nanoplatform performance. Current assessments rely heavily on in vitro systems and animal models that do not fully recapitulate the unique physiological and pathological features of the human bladder. Conventional two-dimensional (2D) cell culture models, although widely used for mechanistic studies and preliminary screening, fail to reproduce key aspects of the bladder microenvironment, including the multilayered urothelial barrier, mucus coating, dynamic urine flow, and tumor–immune interactions. As a result, these systems often overestimate nanoparticle penetration, cellular uptake, and therapeutic efficacy. Furthermore, animal models including subcutaneous and orthotopic bladder tumor models, provide improved biological relevance but still exhibit significant discrepancies with human physiology. Differences in bladder size, urine composition, voiding frequency, and immune system characteristics can substantially influence nanoparticle retention, distribution, and drug release behavior, thereby limiting the predictive value of these models for clinical outcomes. Patient-derived xenograft (PDX) models preserve tumor heterogeneity and genetic features; however, their immunodeficient nature restricts the evaluation of immune-related therapies, particularly for nanotechnology-enabled immunomodulatory strategies. Collectively, these limitations contribute to the frequent mismatch between promising preclinical results and modest clinical efficacy, representing a major bottleneck in the translation of nanomedicine for BCa. Beyond model-related challenges, the unique anatomical and physiological features of the bladder further complicate nanoplatform design. Continuous urine production and periodic voiding lead to rapid dilution and clearance of intravesically administered agents, while the urothelial barrier and mucus layer restrict nanoparticle penetration and tumor accessibility. Although various strategies, including mucoadhesive materials, stimuli-responsive systems, and bioinspired carriers, have been developed to address these issues, achieving a balance between retention, penetration, and biosafety remains challenging. From a regulatory perspective, the lack of standardized evaluation criteria for multifunctional nanoplatforms further hampers clinical translation. Unlike conventional drugs, nanomaterials often integrate diagnostic and therapeutic functionalities, which complicates classification, safety assessment, and approval pathways. In addition, large-scale manufacturing of nanomaterials with consistent physicochemical properties remains technically demanding. To address these challenges, future efforts should prioritize the development of more physiologically relevant evaluation systems, such as organoid models, microfluidic bladder-on-a-chip platforms, and humanized animal models, which can better recapitulate bladder-specific dynamics and improve the predictive accuracy of preclinical studies. Moreover, establishing standardized characterization protocols and integrating data-driven and AI-assisted design strategies may further enhance reproducibility, optimize nanomaterial performance, and accelerate clinical translation. Overall, overcoming these translational barriers will require coordinated advances in materials science, biology, engineering, and regulatory science, ultimately enabling the successful clinical implementation of nanotechnology-enabled precision strategies for BCa. Artificial intelligence-assisted nanomaterial design The integration of artificial intelligence (AI) is fundamentally reshaping the development of nanotechnology-based BCa strategies, introducing unprecedented precision and efficiency into nanomaterial design, treatment planning, and the interpretation of complex diagnostic data [189]. Unlike traditional trial-and-error approaches, AI leverages machine learning (ML), deep neural networks, and generative models to navigate complex material landscapes, significantly accelerating the discovery of nano-systems for targeted drug delivery, intelligent imaging, and synergistic therapy [190]. However, conventional material design strategies are often limited by incomplete understanding of structure–function relationships in complex biological environments such as the bladder, where dynamic urine flow, heterogeneous tumor architecture, and mucus barriers impose additional constraints. To address these limitations, advanced AI models have been developed to capture multiscale interactions and predict material behavior with higher accuracy. The CGformer model, a transformer-enhanced crystal graph network with global attention, demonstrates exceptional capability in predicting material properties by capturing long-range atomic interactions in complex crystals. When applied to high-entropy sodium ion solid-state electrolytes, CGformer reduced the mean absolute error in diffusion energy barrier prediction by 25% compared to conventional models and identified 6 optimal candidates from 148,995 potential structures, with synthesized materials achieving a remarkable Na+ conductivity of 0.256 mS/cm at room temperature [191]. Although such models were initially developed for inorganic materials, they provide a transferable framework for predicting nanomaterial behavior in biomedical contexts, including drug loading efficiency, stability, and interaction with the tumor microenvironment in BCa. Generative AI has been employed to design protein-based nanomedicines by predicting supramolecular self-assembly behaviors, facilitating the engineering of nanocarriers for targeted chemo-, photo-, and immunotherapy [192]. Compared with earlier empirical design approaches, generative models enable the rapid creation of structurally optimized nanocarriers with programmable responsiveness. These approaches allow for the creation of BCa-specific nanomaterials, such as stimuli-responsive nanoparticles that release drugs only in the acidic TME or under oxidative stress, thereby minimizing off-target effects. Furthermore, AI enhances the functional design of nanomaterial systems for BCa through multi-objective co-optimization. While early nanoplatforms were typically optimized for a single parameter (e.g., drug loading or targeting), Bayesian optimization enables simultaneous optimization of multiple design variables, including particle size, surface chemistry, and drug release kinetics [193]. In nanofabrication, Bayesian optimization has been used to simultaneously optimize template geometries and polymer blends for self-assembling block copolymers, resulting in intricate nanopatterns for semiconductor devices [193]. This principle can be extended to design multi-layered nanocarriers that combine imaging contrast agents with therapeutic payloads, ensuring optimal tumor accumulation and real-time treatment monitoring. Extending this concept to BCa, such strategies can facilitate the rational design of multifunctional nanocarriers that integrate imaging and therapy, thereby improving tumor targeting and treatment precision. Additionally, ML algorithms trained on large-scale crystal structure datasets can resolve nanomaterial structures from imperfect experimental data, enabling the characterization of heterogeneous nanoparticles isolated from BCa models [194]. This capability is particularly important for understanding nanoparticle–biological interactions in vivo, where structural heterogeneity can significantly influence diagnostic and therapeutic performance. Therefore, AI-driven nanomaterial design represents a transition from empirical optimization to data-driven and predictive engineering. However, challenges such as limited availability of high-quality biomedical datasets, model interpretability, and validation in clinically relevant BCa models remain key barriers to its widespread application. Future integration of AI with patient-specific data and nanotheranostic platforms may enable fully adaptive and personalized BCa treatment strategies. Future perspectives The long-term objective of nanotheranostics for BCa is the development of clinically viable, adaptive material systems capable of real-time sensing, feedback-regulated therapy, and synergistic multimodal intervention (Fig. 7). Emerging strategies increasingly rely on rational nanomaterial design to couple external energy activation, autonomous motion, and stimulus-responsiveness within integrated platforms, as exemplified by X-ray-activated nanotransducers enabling imaging-guided fractionated photodynamic therapy [10], urea-powered nanobots that exploit the bladder chemical milieu for self-propulsion and enhanced tumor penetration [195, 196] and early concepts of closed-loop systems linking biosensing with on-demand drug release [197]. Concurrently, exploration of advanced material classes, including metal–organic frameworks with programmable degradation and multifunctional therapeutic capacity [198–201], bio-inspired adhesive soft dendritic particles that enhance intravesical retention283, and immunomodulatory nanoplatforms for personalized vaccination and tumor microenvironment remodeling [202, 203], is expanding the functional landscape of nanotheranostics. The integration of artificial intelligence further accelerates this evolution by enabling data-driven material discovery, multi-objective optimization, and predictive modeling of complex nanostructures [189, 191–194]. In parallel, micro/nanorobotic systems capable of active targeting and spatially controlled therapy represent a frontier for overcoming transport and penetration limitations [204–206]. Collectively, future progress will depend on converging intelligent material architectures, AI-assisted design, and controllable actuation mechanisms to realize simplified, adaptive, and translatable nanotheranostic systems for precision BCa intervention. Conclusion This review underscores how rationally engineered inorganic, organic, and hybrid nanomaterials enable the intrinsic coupling of targeting, imaging, and therapeutic functions, establishing multifunctional nanotheranostic platforms governed by structure–function relationships. The integration of complementary imaging and therapeutic modalities within a single nanoscale architecture represents a shift from single-function systems toward adaptive and feedback-regulated material designs. Continued progress will depend on simplifying material architectures while ensuring biocompatibility, manufacturability, and translational robustness, thereby advancing nanotheranostics from conceptual platforms to clinically viable material solutions. Author contributions K.X. conceptualized the study, conducted data curation, developed software, performed formal analysis, and created visualizations. B.Z. contributed to the literature review, domain-specific validation. D.F. assisted with data extraction, reference validation, and contributed to writing. S.Y. and S.L. supported the development of the methodology and preparation of the figures. D.W. and Z.J. provided manuscript editing. F.L. provided overall supervision, guided resource allocation and software strategy, and contributed to the study’s conceptualization and critical manuscript review. M.L. drafted the original manuscript, secured funding and led project administration. All authors reviewed and approved the final version of the manuscript. Funding This study was supported by the Jiangxi Provincial Natural Science Foundation (20253BAC280035) and the Young Scholar Project of the First Affiliated Hospital of Nanchang University (YFYPY202519). Data availability All data generated during the study appear in the submitted article. Declarations Ethics approval and consent to participate The authors have nothing to report. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Kaiwen Xiao and Bailing Zhou contributed equally. Contributor Information Fei Li, Email: feili@uestc.edu.cn. Mohan Liu, Email: liumohan199606@163.com. References Associated Data Data Availability Statement All data generated during the study appear in the submitted article.